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Abstract 
Urinary tract infections are diagnosed in female populations primarily in ambulatory care 
settings in the United States. Yet, published evidence documents that many of the 
antibiotics prescribed in these settings are unnecessary, erroneous, or, inappropriately 
prescribed. Improper management of uncomplicated urinary tract infections in 
nonpregnant women has resulted in higher morbidity rates due to antibiotic resistance. 
The purpose of this retrospective observational cohort study was to explore a current 
national database for associations between nonpregnant American female patients who 
were exposed to poverty and at risk for urinary tract infection antibiotic resistance in an 
ambulatory care setting. Krieger’s ecosocial theory was utilized as the study’s theoretical 
foundation to complement current public health social change priorities. Data from the 
National Ambulatory Medical Care Survey were analyzed to explore potential 
associations with urinary tract infections and antibiotic resistance. The sample consisted 
of ambulatory patients with urinary tract infection symptoms (n=45). The independent 
variables selected were antibiotics prescribed initially in 3 months or less after the onset 
of urinary tract infection symptoms, the continuation of antibiotics prescribed in 12 
months or less after recurrence, and three classes of antibiotics prescribed for urinary 
tract infection symptoms known as broad-spectrum, narrow-spectrum, and combined 
broad- and narrow-spectrum antibiotics, while the dependent variable was urinary tract 
infection antibiotic resistance. Relationships between the variables were analyzed using 
binary logistic regression, however, there were no statistically significant outcomes. 
Promoting antibiotic stewardship programs in all health care settings in the U.S. can 
effect positive social changes that will prevent further antibiotic resistance.
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Chapter 1: Introduction to the Study 
In the first half of the 20th century, the invention and application of antibiotics 
astonished us to treat infections (Davies & Davies, 2010; Landecker, 2015). 
Astonishment has shifted to concern about uncomplicated urinary tract infections (UTIs), 
which medical experts have classified as the primary cause of morbidity in females in the 
United States. (Ciani, Grassi, & Terricone, 2013; Soto, 2014). Disparities in low-income 
female populations demonstrate substandard quality in health care recommendations and 
treatment for uncomplicated UTI infections (Kaiser Family Foundation, 2016). 
Antibiotic-resistance complications in UTIs are now considered a global public health 
crisis (Lee, Cho, Jeong, & Lee, 2013).  
The incidence and prevalence of antibiotic-resistant UTIs in ambulatory care 
settings, which include those settings that are specific to outpatient versus inpatient care, 
have been well-studied across all populations in developing and developed countries 
outside of the United States (August & DeRosa, 2012). Research in ambulatory care 
settings for uncomplicated UTIs in the United States have focused on comparing 
prescribing patterns in pediatric, older adult, and pregnant populations (May, Mullins, & 
Pines, 2014; Matuszkiewicz-Rowynska, Malyszko, & Wieliczko, 2015). Researchers 
have not examined the impact of social determinants such as economic status in the 
prescribing of antibiotics for UTIs in these settings, according to Kobayashi, Shapiro, 
Hersh, Sanchez, and Hicks (2016).  
In 2015, the U.S. Department of Health and Human Services (HHS; 2015) re-
established goals after noting that between 2001-2014, health care disparities had made  
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little progress. Federal initiatives for health care research, policy makers have requested 
that vulnerable community populations such as low-income women be prioritized in 
studies (Agency for Healthcare Research and Quality [AHRQ], 2016). An opportunity 
currently exists to examine the impact of antibiotic resistance and the methods used to 
prescribe antibiotics for uncomplicated UTIs in nonpregnant, low-income women in U.S. 
ambulatory care settings. This study may promote positive social change by helping 
health care practitioners and organizations to reduce barriers in low-income, nonpregnant 
women’s access to quality care in the management of UTIs in ambulatory care settings. 
In Chapter 1, I provide descriptive, clinically-related details about antibiotic 
resistance and UTIs. In support of this study’s direction, I also illustrate the complexities 
of antibiotic resistance patterns related to biomedical implications, epidemiology, 
economic burden, and the global impact of antibiotic resistance in ambulatory care 
settings. Additionally, UTI pathogenicity, clinical significance, epidemiology, economic 
burden, and the relevant impacts of antibiotic prescribing for these infections are 
examined.  
Background 
Urinary Tract Microbiology and Pathogenesis 
The urinary tract system in and out of the human body consists of normal flora. 
Normal flora are also known as common commensals; they present on (exogenous) or in 
(endogenous) humans as gram positive or negative, or fungal organisms (Findley & 
Grice, 2014).  Common commensals may become altered in a human host environment 
due to antibiotic influence, coexisting disease, income, genetics, diet, stress, age, or,  
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environmental factors (Grice & Segre, 2011; Marrie, Swantee, & Hartlen, 1980). Human 
UTIs are the most common type of infection caused by bacteria (Nienhouse et al., 2014). 
UTIs may be caused by voiding urine, when the entryway to the genitourinary tract opens 
(August & De Rosa, 2012). Researchers once thought the inside of the urinary tract to be 
a sterile environment, yet they recently found that bacteria live in the human host (2012; 
Flores-Mireles, Walker, Caparon, & Hultgren, 2015; Hilt et al., 2014; Santiago-
Rodriguez, Ly, Bonilla, & Pride, 2015). Bacteria normally living in the urinary tract may 
cause infections but do not normally lead to death (Nicolle, 2014).  
Urinary Tract Infection Clinical Significance 
Urinary tract infections are clinically significant because urinary tract lab findings 
produce positive results which usually lead to a diagnosis of UTI and subsequent 
antibiotic treatment (Grabe et al., 2014). Researchers conducting global studies have 
found that 50-60% of females under the age of 50 with a low-income status appear to be 
at considerable risk for UTIs (Al-Badir, & Al-Shaikh, 2013; Minardi, d’Anzeo, Cantoro, 
Conti, & Muzzonigro, 2011). Anatomical issues (specifically, the urethral location in 
females) and behavior issues (e.g., noncompliance with medications) appear to correlate 
with poor clinical outcomes related to antimicrobial resistance (Barber, Norton, Spivak, 
& Mulvey, 2013; Minardi, d’Anzeo, Cantoro, Conti, & Muzzonigro, 2011; Mohsin & 
Siddiqui, 2010;). Recurrent UTIs are described as involved in 19% of younger, sexually 
active female populations that have a diagnosis of cystitis, which is a type of lower UTI 
(Soto et al., 2006). When initial treatment fails, recurrent UTIs may develop 
antimicrobial resistance (Ejrnaes, 2010; Bodro, 2015). Clinically-significant management   
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of UTIs, according to Mohsin and Siddique (2010), involves use of evidence-based 
guidelines for the clinical management of infections and is dependent on resources, 
clinical experience, and training.  
Urinary Tract Infection Epidemiology 
Bacterial UTIs are one of the most common infections treated in ambulatory care 
settings (Lema, 2015). Brusch and Bronze (2015) stated that one in five women will be 
diagnosed with a UTI in their lifetime. Data from AHRQ (2014), a U.S. federal health 
care agency, revealed that the incidence of UTIs in ambulatory care settings was highest 
in female patients as evidenced by 13 infections per 10,000 in the broader U.S. 
population. In the hospital setting, it was noted that there were 4 infections per 10,000 in 
the U.S. population, (AHRQ, 2014). Current research data indicate that females with 
complaints of UTI symptoms account for 85% of the 3 million appointments made in 
ambulatory care settings in the United States (Thoureen, Scott, & Best, 2015). In 
nonpregnant females who evidence cystitis for the first time, recurrence occurs at least 
30-44% of the time (Gupta & Trautner, 2013).  
Females of all ages are at risk for UTIs (Lema, 2015). However, women who are 
age 30-60 have a greater incidence of acute UTIs with the mean incidence peak between 
15 to 39 years of age (AHRQ, 2014; Centers for Disease Control & Prevention [CDC], 
2014, 2015). Adult women account for around 10% of all symptomatic UTIs annually, 
and 1 in 3 of these will need antibiotic treatment (Lawal, 2012). Uncomplicated UTIs   
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have been studied without consideration for social determinants in female populations 
(Brusch & Bronze, 2015; Hawker et al., 2014). Researchers have documented that 
hospitalized, pregnant female patients currently have the highest incidence rates of 
complicated UTIs (AHRQ, 2014; Czaja, Scholes, Hooton, & Stamm, 2007).  
Urinary Tract Infection Economic Burden 
Over 9 million ambulatory care visits are made annually in the United States for 
UTIs diagnosed as cystitis (Wagenlehner & Naber, n.d.). Annually, the estimated cost of 
antibiotic agents prescribed for the treatment of symptomatic or asymptomatic UTIs are 
over 1 billion dollars, which accounts for 15% of the total money spent by the public on 
these drugs (Wagenlehner& Naber, n.d.). Poverty, access to care, or inappropriate disease 
management may lead to prolonged or complex care that becomes a significant drain on 
insurance policies carried by groups or individuals (Thorpe, Wisniewski, & Lindsay, 
2009).  
The overall economic burden to patients is high for any disease treatment that 
involves multiple tests and medications. however the costs associated with antibiotic-
resistant UTIs are much higher and account for at least a 35% to 47% increase in total 
patient costs (Roley & Truscott, 2013).  Nonpregnant low-income female populations in 
the United States, in particular, face a considerable financial burden (Shartzer, Long, & 
Benatar, 2015). Medicaid, a source of payment for health care coverage, represents low 
income as a social determinant (Blumberg, 2012). Patients who receive care in 
ambulatory care settings may manifest UTI antibiotic resistance patterns related to having 
Medicaid as their insurance (Alsan et al., 2015). However, studies indicate that even with 
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the Affordable Care Act in place, disparities continue to exist for low-income women 
(Alsan, et al, 2015).  
Antibiotic Resistance Economic Burden 
According to Gandra, Barter, and Laxminarayan (2014), the economic impacts of 
antibiotic resistance in the United States, and the frequency by which the costs directly 
concern the public, health care administration, patients, doctors, and pharmaceutical 
companies, appears to have been poorly documented until recently. Lack of attention to 
these issues has continued to be a concern, Gandra, Bater, and Laxminarayan asserted. In 
the United States, researchers have estimated the economic burden of health care cost for 
infections that are antibiotic-resistant to be approximately $20 billion, with over $34 
billion attributed to a loss in workforce productivity (Bartlett, Gilberg, & Spellberg, 
2013; CDC, 2011a, 2011b, 2015b; Taylor et al., 2014; Song et al., 2015).  
Antibiotic Resistance Biomedical Implications 
Antibiotic drugs are a class of chemical substances that are formed as medicine to 
treat bacterial infections by slowing down or destroying bacterial growth (Fair & Tor, 
2014). McGowan (2008) noted that antibiotic resistance has a significant impact on 
incidence outcomes in community UTIs, for example, resistance to current antibiotic 
agents has increased due to the inappropriate use of these drugs (Nathan & Cars, 2014).   
Antibiotic Resistance Epidemiology 
Antibiotic resistance strain incidence and prevalence rates continue to climb 
without the development of new antibiotics (Hawkey & Jones, 2009). Surveillance efforts 
to generalize and understand the increase in incidence rates of antibiotic-resistant   
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pathogens is confined to the acute care hospital environment (Sydnor & Perl, 2011). 
Limited syndromic surveillance in the community is controlled primarily by the strength 
of funding provided for agricultural and human population studies (Phalkey, Yamamoto, 
Awate, & Marx, 2013). Ongoing efforts to establish campaigns to promote judicious use 
of all antibiotics continue in the United States (Purcell, 2012). However, as awareness 
grows, the pace for the creation of new antibiotics has slowed (Boucher et al., 2009; 
Sundqvist, 2014). Failure to provide a solution for antibiotic-resistant infections has led 
to the escalation of human, human-to-animal, and animal-to-human pathogenic 
transmission (Hawkey & Jones, 2009). 
Problem Statement 
The current public health-antibiotic-resistance crisis is due to inappropriate 
infection management as evidenced by many factors. Low-income populations are at a 
higher risk for antibiotic resistance due to the inappropriate medical management of 
infectious diseases (Shartzer et al., 2015). Inappropriate antibiotic prescribing has also 
been reported with over 47 million (more than 30%) antibiotics prescribed annually in the 
United States. (Shapiro, Hicks, Pavia, & Hersh, 2013; Ventola, 2015). Urinary tract 
infection diagnosis in U.S. female populations comprises more than 84% of the 3 million 
patients who report to ambulatory care facilities with UTI symptoms (Thoureen, Scott, & 
Best, 2015). The CDC (2013a) reported that 50% of the antibiotics that are prescribed in 
ambulatory care settings are unnecessary or suboptimal and, also, empirically prescribed 
without laboratory confirmation of an infection. Health-care providers are challenged to 
provide low-cost, generic substitutions when dictated by insurance plans; many  
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antibiotics may not have a generic substitution (Garau, Nicolau, & Bassetti, 2014; 
Pronovost, 2013).  
The rate of uncomplicated UTIs in women between the ages of 18-49 in the 
United States who are managed in the ambulatory care setting and receive antibiotic 
treatment is 28.2% for every 10,000 females (Lawal, 2012). Pregnant, pediatric, or older 
adult females with a lower economic status in developed countries such as the United 
States are often reported in the literature as having a high risk for antibiotic-resistant 
infections such as UTIs (Lawal, 2012). Research reports since the 1980’s provide 
evidence that inappropriate patient infection management by providers is the primary 
problem leading to antibiotic resistance in UTIs (Vasudevan, 2014).  
A gap in the literature exists because U.S. researchers have not examined income 
distribution in nonpregnant females with UTI complaints in ambulatory care settings 
(Kobayashi, 2016; May et al., 2014). An opportunity existed to study nonpregnant 
females, with Medicaid recipient status representing low-income status. This research gap 
has contributed to antibiotic-resistant UTIs in a population already known to be high-risk 
(Ciani et al., 2013). Social change can occur by studying the exposures and risks related 
to ambulatory care antibiotic management for UTIs. This social change concept to study 
UTI antibiotic management suggested further that there is logic to seeking an increase in 
funding for future research. For example, research could  
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include case-control studies aimed at improving care management of all health care 
problems in low-income populations in ambulatory care settings.  
Purpose of the Study 
The purpose of this quantitative study was to examine nonpregnant American 
female patients who were exposed to poverty, as evidenced by the reported payment type 
of Medicaid, as the reported payment type, and at risk for antibiotic resistance when 
seeking care for UTIs in ambulatory care settings. Low-income indicators such as 
insurance type may negatively impact outcomes of antibiotic resistance reduction efforts 
(Laxminarayan et al., 2013). The significance of this study contributed to the increase in 
awareness of risks of antibiotic resistance related to poor outcomes in uncomplicated 
infections such as UTIs.  This study was designed to predict outcomes that are associated 
with risks related to antibiotic resistance in low-income nonpregnant female populations 
on Medicaid.    
Research Questions and Hypotheses 
Three research questions governed this study. The outcome (or, dependent) 
variable of interest was UTI antibiotic resistance (UAR). The independent variables were 
initial antibiotics, continued antibiotics, and broad-spectrum, narrow-spectrum, and a 
combination of broad- and narrow-spectrum antibiotics prescribed. The research 
questions were grounded by the ecosocial theory. This study’s research questions 
incorporated proximal and distal associations with disease process and outcomes. 
Krieger, the founder of ecosocial theory (2008), stated that proximal associations can 
only be changed by a patient or his or her provider; however, society must work to   
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change distal associations such as payment amounts for provider services (p. 223). Social 
patterns constantly change due to pathways, power, and levels that are proximally and 
distally associated (2008).  
Research Question 1: Are initial antibiotics prescribed for UTIs associated with 
UTI antibiotic resistance?  
H01: There is no statistically significant association between antibiotic resistance 
in UTIs and initial antibiotics prescribed.  
Ha1: There is a statistically significant association between antibiotic resistance in 
UTIs and initial antibiotics prescribed.  
Research Question 2: Are continued antibiotics prescribed for UTIs associated 
with UTI antibiotic resistance?  
H02: There is no statistically significant association between antibiotic resistance 
in UTIs and continued antibiotics prescribed.  
Ha2: There is a statistically significant association between antibiotic resistance in 
UTIs and continued antibiotics prescribed.  
Research Question 3: Is the class of antibiotic prescribed for UTIs associated with 
UTI antibiotic resistance?  
H03: There is no statistically significant association between UTI antibiotic 
resistance and class of antibiotic prescribed.  
Ha3: There is a statistically significant association between UTI antibiotic 
resistance and class of antibiotic prescribed.  
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Theoretical Foundation 
The theoretical framework for this research study was grounded in Krieger’s 
(2001) ecosocial theory. Chapter 2 will contain a more detailed discussion about this 
theory. This theory speaks to the criticality of social change and population disease 
patterns (Krieger, 2001, p. 668). The importance lies in both the biological and societal 
components of change specific to the epidemiology of the responsibility of social 
inequality (p. 670). Krieger (2001) produced 4 constructs that are central to Ecosocial 
Theory and relate to this dissertation project: “accountability and agency, embodiment, 
the cumulative interplay of exposure, susceptibility and resistance, and pathways of 
embodiment” (Krieger, 2008). The ecosocial theory (2001) approach works well with the 
structural levels of populations and those disease outcomes that can be associated with 
multiple population types.  
Nature of the Study 
A retrospective, observational cohort design methodology was used to describe 
the relationship between the incidence of the dependent variable, antimicrobial resistant 
UTIs, and the role of the independent variables of initial antibiotics, continued 
antibiotics, broad-spectrum antibiotics, narrow-spectrum antibiotics, a combination of 
both broad- and narrow-spectrum antibiotics. The variables were utilized to study 
nonpregnant American women who were between the ages of 25-44, on Medicaid, and 
sought care for UTI symptoms in ambulatory care clinics. The data was abstracted from a 
public, national database source known as the National Ambulatory Medical Care Survey 
(NAMCS). The database was composed of U.S. national ambulatory setting  
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demographic, payment, pharmaceutical, diagnostic, and laboratory, data needed for this 
study. The patient data collected in NAMCS was queried for the selection of variables 
that met criteria of less than 3 months (initial antibiotics prescribed), and 12 months or 
less (for those antibiotics that were continued). After review of baseline data abstracted, 
the dependent variable, antibiotic-resistant UTI was queried. Additional independent 
variables of broad-spectrum, narrow-spectrum, and broad- and narrow-spectrum 
combined antibiotics were queried. Multiple logistic regression was utilized to analyze 
patient criteria data.  
Definitions 
Following are definitions for important terms related to the variables and ideas 
discussed in this study:  
Aerobic organisms: Organisms that need oxygen to survive (Maier, Anderson, & 
Roy, 2015; Murphy & Frick, 2012).  
Anaerobic organisms: Organisms that live in direct proximity to the genitourinary 
tract and that do not require oxygen to live (Maier, Anderson, & Roy, 2015; Murphy & 
Frick, 2012).  
Antibiotic resistance: A situation that occurs when the efficacy of a drug used in 
the treatment of infections is compromised (Smith et al., 2014; Zur Wiesch, Kouyos, 
Engelstadter, Regoes, & Bonhoeffer, 2011).  
Antibiotic susceptibility tests: Used to determine what the pathogen will respond 
to for antibiotic treatment. Utilized by providers in the treatment of infections. Reported 
out as a “MIC” or “minimum inhibitory concentration” (Street & Staros, 2014).  
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Broad-spectrum antibiotics: Antibiotics used for empiric therapy when the 
microorganism is unknown (Pallett & Hand, 2010).  
Clinical classifications: Infections involving a variety of tracts in the human body 
(Brede & Shoskes, 2011).  
Common commensals: Nonpathogenic microorganisms which have a primary 
duty to keep humans healthy (Todar, n.d.). 
Narrow-spectrum antibiotic: Antibiotic that can target a specific microorganism 
(Pallett & Hand, 2010). 
Recurrent UTI: Recurrence with UTIs is typically defined as three or more UTIs 
within 12 months, or two or more occurrences within six months (Arnold, Hehn, & Klein, 
2016). 
Voiding: The human act of urinating. Takes place in the genitourinary tract with 
the byproduct being urine (Whiteside et al., 2015; Wolfe & Brubaker, 2015). 
Assumptions 
In this research, I assumed that the risks for UTI antibiotic resistance in 
nonpregnant females, ages 25-44, on Medicaid, and symptomatic with an uncomplicated 
UTI regardless of economic status, were not statistically significant among U.S. 
ambulatory care settings. According to Garau, Nicolau, Wullt, & Bassetti (2014) 
antibiotic consumption and antibiotic resistance directly correlate with one another; 
resistance in UTIs after receiving broad-spectrum antibiotics occurs in 55.3 per 100,000 
(women) due to inappropriate antibiotic prescribing.   
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An additional assumption that was that all diagnoses were made per laboratory 
standards, and, licensed health-care providers assessed clinical signs and symptoms. 
Laboratory tests are assumed to be governed by the FDA and standard laboratory testing 
regulations. Assumptions related to regression analytics that were deployed were that the 
DV was dichotomous; the factor level “1” represented the desired outcome. It was 
additionally assumed that there would be more than one IV, and that they would be 
categorical. It was also assumed that because regression was utilized that a linear 
relationship would not be necessary, residuals did not need to be normally distributed, 
and homoscedasticity was not needed for each level of IV. Although I did not collect the 
data in the national database that I used, a review of the original data collection method 
was reviewed and it was assumed that the accuracy of the data was solid.  
Scope and Delimitations 
Inappropriate management practice for UTIs that includes antibiotic prescribing 
practices, accounts for greater than 150 million ambulatory care visits per year. Of the 
number of visits per year, more than 13% of all ambulatory care visits provide around 47 
million unnecessary prescriptions (The Pew Charitable Trusts, 2016). Clinical guidelines 
may not be followed for lower socioeconomic status patients in the treatment of urinary 
tract infections. Less costly generic antibiotics, even when known to go against treatment 
guidelines, are often prescribed for lower income populations (Denes, Prouzergue, 
Ducroix-Roubertou, Aupetit, & Weinbreck, 2012). In addition to antibiotic prescribing, 
there may be multiple other factors placing low-economic populations at risk for 
antibiotic resistance in the United States.  The study focus was to abstract a cohort sample   
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of ambulatory care data (physician-patient encounter/visit) from U.S. regions. I had 
identified a national survey database to use, the National Ambulatory Medical Care 
Survey (NAMCS) (2008- 2012).  This database was utilized in the review for risks with 
UTI antibiotic management in low-income populations as identified by the independent 
variable, Medicaid.  
Ambulatory clinic sampling included only non-federally funded offices and did 
not include ambulatory visits via phone, house calls, pediatric-specific, or those 
ambulatory care offices within an acute care health care facility. Population sampling for 
this study included nonpregnant females between the ages of 25-44 on Medicaid with 
indicators (diagnosis, medication, reasons for visit, symptoms) that were positive for 
urinary tract infection. The CDC and only one other study in 2006 reported that women 
between the ages of 25-44 were most likely to become resistant to antibiotic medications 
(Butler, Hillier, Roberts, & Dunstan, 2006; CDC, 2011a). Low-income female 
populations were represented by using Medicaid payment data available in the national 
data sets that indicated insurance type. The categories of females utilized by regional U.S. 
studies may not accurately represent all counties within those U.S. regions, therefore, the 
delimitations may not represent boundaries that I would have clearly made had I 
originally produced the datasets. 
Limitations 
The data utilized from the national database was intended to be utilized for this 
research study. The study data may have been flawed, due to the choice of a retrospective 
design. I used a large, national, and public database set that originated in   
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the United States. Additionally, though the database used was large, there was no 
guarantee that enough subjects would be available with the outcome being investigated.  
A prospective approach with a cohort study may be a better choice, however the time and 
expense of such a study was not feasible.  
Significance 
Researchers have indicated that there is a potential relationship between infection 
management outcomes and risks for UTI antibiotic resistance related to multiple factors, 
including prescribing practices in the inpatient acute setting (i.e., hospital) (Shapiro et al., 
2013). Research published, however, has not adequately supported the critical need for 
social change that is focused on UTI clinical management of impoverished nonpregnant 
females, such as those on Medicaid, in U.S. ambulatory care settings (Kodner & Gupton, 
2010). Urinary tract infections and antibiotic resistance prevention progress have been 
confined to pediatric, elderly female, pregnant female populations, or hospital-related 
data sources. The literature has not produced quantitative values that can be clinically 
correlated and can be applied to prevention effort applications in nonpregnant low-
income female populations in ambulatory care settings. Furthermore, access to the 
reliable patient, prescriber, pharmaceutical, laboratory testing and payment data had not 
been simultaneously available in ambulatory care.  
Factors significant for social change patterns are currently evident. Relevant 
epidemiology studies about antibiotic-resistant UTIs and the economic impacts on 
specific populations with a high incidence of disease burden related to inappropriate   
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treatment greatly impacts federal and state funding. Federal regulators such as the 
Centers for Medicare and Medicaid Services (CMS) have already mandated antibiotic 
stewardship (ABS) programs in hospitals as part of their conditions of participation 
(Centers for Medicare and Medicaid Services [CMS], 2012). CMS states that unless all 
efforts to reduce healthcare-acquired infections (HAIs) has been made, including the 
implementation of an ABS program, they will not reimburse hospitals for infections after 
patients are admitted and in their care. Recommendations to introduce the same ABS 
programs in long-term care facilities has additionally been proposed (CMS, 2015). It 
would be likely that ambulatory care would be a future target for ABS with CMS.  
UTIs and antimicrobial resistance are predominant global health problems that are 
associated with all ambulatory care patients (Frieden, 2010). Antibiotic treatment choices 
in ambulatory care can greatly impact morbidity and mortality due to antibiotic resistance 
(Yang et al., 2013). Community populations are not only associated with antibiotic 
resistance in UTIs, but the exposures to inappropriate antibiotic treatment may go 
unnoticed. To what extent this damage is causing may not yet be quantifiable. Databases 
produced via retrospective collection by health care facilities, universities, state and 
federal antibiotic-resistance research are becoming available for trend investigation. 
Local hospital infection control or state syndromic surveillance data programs are in 
place. These programs apply real-time (active surveillance) data collection techniques to 
prevent harm to patients (CMS, 2016).   
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Summary 
Urinary tract infection epidemiology and the economic burden have changed over 
the last few decades. The current climate of antibiotic resistance has become an 
emergency. Urinary tract infections rely on the appropriate treatment with antibiotics.  
Nonpregnant, low-income female populations, ages 25-44, with UTI symptoms, and 
seeking care in ambulatory settings, has been a population in the United States lacking 
research studies. Many unknowns have existed that include access to care issues, patient 
behaviors, and provider prescribing habits. Those patients who become mismanaged with 
antibiotics greatly contribute to the morbidity and mortality of the UTI rate increase 
found in community ambulatory care populations.   
A review of the literature will be discussed and evaluated in Chapter 2. The 
relationship between UTIs and antibiotic resistance and antibiotic management will be 
additionally characterized. The literature review will seek to inform readers about the 
antibiotic resistance gap in U.S. ambulatory care settings, and nonpregnant, low-income 
women with UTIs. Variables such as broad-spectrum and narrow-spectrum antibiotics 
were chosen to better understand the utilization and outcome relationships of these drugs 
prescribed for UTIs. An evaluation of those gaps in the literature related to antibiotic 
resistance patterns in ambulatory care, low-income populations, will be discussed. The 
methodology will be revealed in Chapter 3, which will represent my intentions of how 
the research will be accomplished. Chapter 3 will report out how this study answered the 
questions that I had proposed. Additionally, I will illustrate how the study variables, 
ethics, and data will be managed. Finally, the outline of the study results, findings, and 
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implications for social change will be covered in Chapters 4 and 5.  The final pages of the 
dissertation document will include the references and appendices.   
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Chapter 2: Literature Review 
Introduction 
This literature review was conducted to understand historical and current research 
related to UTI antibiotic resistance and how this research is related to antibiotic treatment 
in nonpregnant low socioeconomic status females in ambulatory care settings. Chapter 2 
includes an overview of historical and contemporary beliefs about UTI antibiotic 
resistance and how those models have been applied to low-income populations. I 
searched various databases and then reduced my results to include only those studies and 
articles that were the most germane to this study.  
The chapter will begin with a discussion about ecosocial theory (Krieger, 2008), 
which I used to ground this study. The fundamental epidemiological history of UTIs and 
the microbiology of antibiotic-resistant UTIs will also be discussed. In the literature 
review, I will additionally include data that support an issue of volatility with antibiotic 
prescribing for UTIs in ambulatory care settings in low-income female populations in 
developing countries, and comparatively, in the United States. Furthermore, this 
discussion will include antibiotic stewardship with research-based evidence about 
antibiotic utilization and how it can be negatively associated with antibiotic resistance in 
UTIs. In the closing segment, I will examine the variables and related literature that I 
used in my investigation. I developed my research methodology based on my review of 
the literature.  
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Literature Search Strategy 
I conducted a comprehensive, computerized literature search to obtain abstracts 
and published documents relevant via PUBMED, PLoS, Cochrane Database of 
Systematic Reviews, Walden University ProQuest Dissertations database, CORE, CDC 
database and web pages, The Centers for Medicare and Medicaid database and web 
pages, the World Health Organization website, PubMed Central, BioMed Central 
Hopkins Medicine website, Pacific Group of e-Journals, Wiley Online Library, American 
Society of Microbiology library web site, Agency for Research and Quality database and 
website, Whitehouse.gov website, Journal Storage online library, Wisconsin Public 
Library system.  
The 194 documents chosen were based on the most relevant and recent mainly 
between the years’ 2011-2017, except for documents containing historical perspectives, 
last-known published findings about my topic, or those years that establish the theory 
which I used. A variety of keywords were utilized independently and in combination with 
one another in exploring the literature. These included urinary tract infection, Medicaid, 
U.S., antibiotic resistance, antibiotic use, low-income female, antibiotic stewardship, 
antibiotic prescribing, primary health care, and ambulatory care.   
Theoretical Foundation 
Krieger (2001) described social change and population health patterns as critical 
elements (p. 668) of change that is specific to the responsibility of social inequality in 
epidemiology. Within the health care community, the spotlight is on population health, 
disease distribution of pathogenic organisms, environmental triggers causing disease, and 
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social inequalities which could advance human infectious disease states (Gulis & Fujino, 
2015).  These focal points are evident in key ecosocial theory (Krieger, 2008). Principal 
areas identified by Krieger (2008) are levels, pathways, and power: accountability and 
agency, embodiment, the cumulative interplay of exposure, susceptibility and resistance, 
and pathways of the embodiment (p. 224). According to Krieger social patterns exist in 
all populations and constantly change, however they do not appear to be economic and 
political priorities, which result in disparities in unsupported health care endeavors.  
Krieger (1994) was the original founder of ecosocial theory (see Figure 1.). This 
prototype demonstrates that a change in any of the pathways will alter the life course of 
human health. In any population analysis of disease changes, researchers should take into 
consideration the causal pathways operating on many diverse levels and spatiotemporal 
systems (p. 224) as well as examine historical events to describe the burden in disease 
population distribution and inequality patterns as populations have changed over time 
(Krieger, 2008).  
Krieger (2008) stated that the ecosocial model exposes how proximal and distal 
factors change socially (p.233). Proximal factors include those that can be controlled by a 
person or by a medical health professional, and distal factors include those factors that 
society will have to change (Krieger, 2012). She explained that her theory is an 
amplification of the concepts of the gene-environment interaction framework which 
posits that individual variations in genetic makeup are extrinsically related to a composite 
of disease that has occurred in the human host (Krieger, 1994, 2008; see, also, CDC,   
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2016; National Human Genome Research Institute [NHGRI], 2014). Pharmaceutical 
interventions that could halt the expression of those genes and which may be biologically 
susceptible to disease have been the focus of this type of gene-environment research 
(Krieger, 2008). Exposures to cumulative pathogenic, behavioral, environmental, and 
physical processes (promote gene expression) are what Krieger (2008) refers to as the 
proximal associations that cause disease (p. 233).  
The value of the ecosocial theory for this study is to augment the principle 
foundations of UTI, antibiotic resistance, and those roles and influential characteristics of 
prescribing antibiotics in a non-pregnant, low-income female population. Social 
inequality as described by Krieger (2008), was utilized by the authors, Green and 
Labonte as a blueprint for their book written about public health policy and pathogenic 
economic justice in developing countries and the United States. At the center of the 
ecosocial theory are the pathways of population distribution operating within multiple 
phases of the infection evolution of UTI. Penders, Stobberingh, Savelkoul, & Wolffs 
(2013) investigated how the influence of cultures, geography, and population density may 
determine antibiotic susceptibility. Penders et al. (2013) provided evidence indicating a 
pathogenic resistance of various organisms that cause UTIs in humans. This study 
demonstrates the population distribution relationship posited by Krieger on emerging 
antibiotic resistance and how important culture-based studies continue to be even in an 
era focused on genetic research.   
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Pathways of Ecosocial Theory 
Antibiotic resistance can be attributed to the inadequate prescribing of antibiotics, 
the innocent patient, or a health-care provider type discrepancy due to lack of availability 
in the geographical area of care a patient (Sahoo, Tamhankar, Johansson, & Lundborg, 
2010). Population distribution influences the levels segment as well health-care provider 
prescribing competency (2013). Additionally, there may be population factors of a 
prescription response relationship between low-income female populations and the 
buildup of resistance that is even due to minimal antibiotic exposure (2013). Social 
constructs that include individual, household, or regional groups may manipulate the 
choices found in the pursuit of health treatment. Antibiotic resistance with UTIs may 
occur if the “power” and exposure to internal or external forces (i.e.., access to quality 
care within a hospital or out in the community) is negatively supported by a remote 
geographical region or political environment (McDonnell Norms Group, 2008; Brusch & 
Bronze, 2015). 
Power of Ecosocial Theory 
Krieger (2008) used the diagram to describe conservation ecology of forests and 
disease to describe population disease distribution. The diagram was used to detail the 
complexity of temporal (old or young forests) and spatial (big or small forests) metrics 
seen in ecology (2008). Temporal studies have been conducted on antibiotic-resistant 
UTIs encountered in developing countries (Guyomard-Rabinirina et al., 2016). Antibiotic 
resistance and UTIs have been found to be like that of a U.S. forest when portrayed as “a 
level,” either on an individual or group level, which is central to Krieger’s ecosocial   
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theory (p. 224). The impact on spatial issues arise in forests the same as UTIs in humans, 
when zoonotic disease such as those that are tickborne (i.e., Babesiosis or Rocky 
Mountain Spotted Fever) (LymeDisease.org, 2015) increase in incidence because the size 
and location of a forest changes due to excessive commercial logging operations within a 
given area (2008). Similarly, UTIs increase in incidence in geographical regions due to 
excessive overutilization of antibiotics (Rowe & Manisha, 2013). The distribution of 
forest species may also shift negatively in two ways: increase in those species that are 
destructive and transmit a dangerous disease to humans and other woodland creatures, or, 
forest species whose purpose is to keep other harmful species from emerging or 
overpopulation Martins da Costa, Loureiro, & Matos. (2013). Comparatively the same 
can be described with antibiotic use and emerging resistance patterns of transmission of 
antibiotic resistance in humans as studied by Mamuye, Metaferia, Birhanu, Desta, and 
Fantaw (2015) that portray Krieger’s theories as they relate to UTI resistance today.  
Levels of Ecosocial Theory 
Krieger notes that a population can become quickly eroded because of community 
epidemics (2008). She used the example of measles as an argument of how perceptions of 
those experiences in a population are rapidly threatened: if measles appeared endemic 
within a community (level) the population must exceed a specified number of people 
(scale), to identify and understand the cause of the problem as an epidemic before it 
becomes endemic (p. 225). When one is considered and not the other (i.e., a level) the 
events going on within the population can cripple the community residents if they are not   
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recognized (2008). These factors interact to increase the rate of infectious disease and 
may lead to community disintegration (p. 224).  
Krieger additionally mapped out a hierarchy of distance that is described by 
public health as “distal to proximal” as an explanation for epidemic disease (2008, p. 
222). Krieger attempted to delete this terminology and replace with “levels, pathways, 
and power” (p. 228). Krieger’s use of a map (p. 224) was equal to a hands-on approach, 
and supported the arguments she made for how biological and societal disease patterns 
originate based on affordability and political agendas. Living standards are associated 
with race and social class as she explained which has a tremendous impact on outcomes 
with patient and the prescribing of antibiotics due to these agencies regulate who (class of 
patient), what (approve types of drugs for use), and how (public health funded or private) 
our communities are cared for (2008). For example, if the economic trend in public health 
is to cut funding for syphilis surveillance in young female pregnant populations whose 
incidence has been rising (CDC, 2015e), initial antibiotic prescribing can impact 
community prevalence and the spread of this disease. In chapter 2 of this paper, a 
description of the ecological forces and relationships involved in pathogenic responses 
related to antibiotic prescribing and ambulatory care patient interactions with health care 
that has led to antibiotic resistance is illustrated by Krieger’s’ ecosocial theory.  
Literature Review Related to Key Variables and/or Concepts 
Antibiotic resistance patterns appear to be progressing in intensity and worldwide 
distribution as mankind perseveres in the war on resistant microorganisms (World Health   
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Organization [WHO], 2014). It is well understood that antibiotic resistance is purely 
guided by utilization (Lee et al., 2014). Daniel et al. (2014) report that in the United 
States over 200 million prescriptions are provided to outpatient populations for the 
treatment of viral infections alone.  
Current State of Antibiotic Resistance 
New antibiotic drugs to treat infections need to be developed to keep pace with 
resistance (Boucher et al., 2009). One early research initiative to reduce inappropriate 
antibiotic utilization analyzed 39 Cochrane studies (Cochrane.org; 2005) and learned that 
viral illness will improve on their own if patients are provided with prescriptions and then 
asked to delay filling prescriptions for two to three days. By not filling a prescription, the 
percent chance of antibiotic resistance is reduced to zero (Bartlett, Gilberg, & Spellberg, 
2013). Regardless of how perfectly this is understood, inappropriate utilization continues.   
In the United States, health-care providers make poor choices in the prescribing of 
antibiotics 50% of the time (CDC, 2013a). Over the last century, it had been possible to 
control antibiotic prescribing for infections and observe susceptibility without the 
conferral of antimicrobial resistance (Davies & Davies, 2010). Today, antibiotic 
resistance patterns have accelerated (Hawkey, 2008). The treatment of infections without 
resistance is no longer under our human control (President’s Council of Advisors on 
Science and Technology [PCAST], 2014). The effects now span to all classes of 
antibiotics with many pathogenic isolates, at local, national, and global levels (2010). 
Efforts to protect those classes of antibiotics that produce rare resistance has become a 
worldwide priority (Carlet et al., 2012; 2014).   
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Epidemiology of Antibiotic Resistance 
Annually, antibiotic resistance distribution rates associated with morbidity and 
mortality are published in the United States, the CDC (Centers for Disease Control & 
Prevention [CDC], 2013b) shows that approximately 23 million deaths occur annually as 
a direct result of infections that are resistant to one or more classes of antibiotics. 
Children in the 1-5-year-old age range have been identified in the United States as one 
population with antibiotic resistance increasing, however the variability in geographic 
area, methods of surveillance and data collection, and the identification of risk factors as 
well as prevalence will need to be researched further (Rush University Medical Center 
[RUMC], 2014; Bryce et al., 2016).  
Current UTI prevalence. The prevalence of antibiotic-resistant UTIs in pregnant 
women, the most common complication in pregnancy, is also increasing. Rizvi et al. 
(2011) studied 4,290 urine samples from pregnant females and identified prevalence rates 
of 78% for asymptomatic bacteriuria (n=3210) and 25.2% (n=1080) with symptomatic 
UTIs. Pregnant females, unlike nonpregnant females in the United States, regardless of 
socioeconomic status, are managed with antibiotic medications for both asymptomatic 
bacteriuria and symptomatic due to the known high morbidity caused by untreated UTIs 
(2011). The prevalence rate of UTIs in the United States in nonpregnant females who 
seek care in ambulatory care settings has not been published other than to mention that 
85% of UTIs occur in both the pregnant and nonpregnant female populations. Prevalence 
rates in ambulatory care settings for nonpregnant females who are dependent on 
assistance with insurance, such as Medicaid, for UTIs, to date, has not been published. 
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Pregnant females, unlike nonpregnant females, have had regular infusions of unrestricted 
grant funding for studies to support protocols and further research studies related to 
antibiotic resistance (Martinez de Tejada, 2014). Nearly 2 million people in the adult U.S. 
population (p. 11) have died or will have died of serious complications because of 
antibiotic resistance and were treated by drugs that were designed specifically to 
eliminate harmful pathogens (Food & Drug Administration [FDA], 2011; Fair & Tor, 
2014). The declining effectiveness of antibiotics due to negative outcomes such as 
mortality, raise concern over the costs that produce widespread economic burden 
(Gandra, Barter & Laxminarayan, 2014).  
Economic Burden of Antibiotic Resistance 
The annual economic burden estimated at over 60 billion dollars indicates that of 
this amount, 35 billion dollars in productivity costs are lost that are directly attributable to 
antibiotic resistance in the United States (Centers for Disease Control & Prevention 
[CDC], 2013b; Network for Excellence in Health Innovations [NEHI], 2013). Although it 
is a challenge to measure the economic burden of antibiotic resistance it is projected that 
by the year 2050 over 100 trillion dollars and 10 million deaths will contribute to 
economic loss associated with this problem (O'Neill, 2014). A macroeconomic approach 
must be carried out in any future studies per Gandra et al. (2014) to quantify the true 
economic influences of antibiotic resistance. Currently, in the United States there are 
substantial financial and clinical burdens related to several pathogens causing dangerous 
levels of resistance (Centers for Disease Control & Prevention [CDC], 2015c).  
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Antibiotic Utilization 
Multiple factors today impair antibiotic treatment and lead to antibiotic resistance, 
(CDC, 2013a, p. 11). In ambulatory care, the most common antibiotics used are those 
prescribed for seasonal viral medical conditions caused by pathogens that do not require 
antibiotic treatment (Shapiro et al., 2013). Examples of medical conditions that do not 
need antibiotics are cold and Flu viruses (Centers for Disease Control & Prevention 
[CDC], 2015d). There are times when these viruses cause an illness that exacerbates 
another underlying medical disease process already in progress (Singanayagam, Joshi, 
Mallia, & Johnston, 2012). The lowered resistance due to viruses combined with chronic 
disease processes can trigger or further promote bacterial growth in an organ’s location of 
chronic disease (Kurai, Saraya, Ishii, & Takizawa, 2013; Yamaya, 2012). For example, 
an individual with Chronic Obstructive Pulmonary Disease (COPD), a chronic 
respiratory disease, acquires Influenza (a respiratory illness) and may be more susceptible 
to bacterial pneumonia (a different respiratory illness).  
 Broad-spectrum antibiotics. Antibiotics that cover many different pathogens 
utilized by ambulatory care providers are known as Broad-Spectrum antibiotics (Shapiro 
et al., 2013). Two classes of broad-spectrum antibiotics, macrolides, and 
fluoroquinolones, are used the most. Studies to understand our current state of antibiotic 
resistance related to the misuse in antibiotic selection type is needed (Shapiro, Pavia, & 
Shah, 2011; Walker, 2013).   
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Epidemiologically Significant Pathogen Emergence 
The CDC has compiled a list of hazardous antibiotic-resistant pathogens that 
often accompany inappropriate prescribing of antibiotics; these pathogens represent an 
“urgent, serious, or concerning” threat and are quickly progressing antibiotic resistance 
patterns (Golkar, Bagasra, & Pace, 2014; CDC, 2015c).  
Threat levels defined. An “urgent” threat is the most serious due to that there is a 
high risk for widespread antibiotic resistance to occur. A “serious” threat describes 
behaviors in pathogens identified that may worsen if they are not closely monitored. 
Finally, a “concerning” threat may be stated as a low-risk because the choices for 
antibiotics are still many, however, severe illness can also still occur. These threats were 
defined by a level of harm thought to be caused by the pathogens identified and intended 
to be utilized for prevention purposes with epidemiology surveillance programs (CDC, 
2015c).  
Urgent threats. Larger urban populations produce antibiotic-resistant pathogens 
that would be considered “urgent” on the CDC threat list. Since the year 2000, key 
“urgent” pathogens known as Carbapenem-resistant Enterobacteriaceae (CRE) or 
Carbapenem-resistant Klebsiella pneumoniae (CRKP) have increased from less than 1% 
to greater than 12% in larger urban regions (Satlin, Jenkins, & Walsh, 2014). It is not 
unusual to find a 50% mortality rate (p. 1) of infection in major medical centers in large 
urban areas where complicated procedures such as solid organ transplant (SOT) are 
performed. Facilities that provide SOT have been reporting CRKP infection incidence 
rates at or greater than 10% (Satlin et al., 2014, p. 2).   
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In a metanalysis of liver transplant patients, the mortality incidence was five-fold 
higher in those patients with CRKP infections identified postoperatively in a hospital 
setting (Kalpoe et al., 2012). In contrast, a different study discussed that healthcare 
personnel working in an ambulatory setting of one western U.S. region took a model 
approach to carbapenem-resistance prevention to prove that these resistant pathogens 
could be decreased (Lee et al., 2016). The authors applied the principles provided in the 
CDC carbapenem resistance toolkit to simulate a decrease in carbapenem-resistant 
pathogens. The health care workers conducting the study had identified that by the year 
2025 carbapenem-resistant pathogens would grow to endemic proportions, however by 
utilizing this toolkit, they were able to prove a 50% reduction in incidence rates in the 
population (Lee et al., 2016).  
Serious threats. Other important antibiotic-resistant pathogens in addition to 
carbapenem-resistant pathogens have indicated a slow upward trend developing in 
community-acquired antibiotic resistance in various regions in the U.S. pathogens include 
Vancomycin-resistant Enterococcus (VRE), multidrug-resistant Pseudomonas 
aeruginosa (MDR-PA), Imipenem-resistant Acinetobacter baumannii (CR-Ab), and 
resistant Escherichia coli and Klebsiella pneumonia, both of which are known as 
“Extended Spectrum Beta Lactamase” (ESBLs) due to that they are resistant to third 
generation cephalosporins (aka, Beta Lactam antibiotics) (Lee et al., 2013). VRE is often 
found in immunocompromised patients if it is a true infection, however, there is a high 
prevalence of carriage in the community (Byappanahalli, Nevers, Korajkic, Staley, & 
Harwood, 2012). Methicillin-resistant Staphylococcus aureus (MRSA) was said to have   
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been increasing in incidence and prevalence in the community over the last decade 
(Mekviwattanawong, Srifuengfung, Chokepaibulkit, Lohsiriwat, Thamlikitkul, 2006). In 
2010, however, a newer study by the CDC was released that indicated a decrease in 
community MRSA (Kallen et al., 2010).   
Concerning threats. In many geographic regions in the United States, MRSA is 
now considered endemic (David & Daum, 2010). Endemicity does not lessen the 
virulence of this pathogen, however. Many of those pathogens previously discussed are 
carried on a person’s body as normal flora (Borchert et al., 2008). Lowering of the 
immune status may predispose a person to illness as healthy humans are able to coexist 
with their normal flora, even pathogens (Harvard Health Publications, 2015). Pathogens, 
however, rapidly learn and adapt faster than antibiotics are produced (Childress, 2013). 
Strategic deployment of effective and sustainable activities with antibiotic stewardship 
using education as a multidisciplinary tool, are necessary (Azevedo, Capela, Baltazar, 
2013) 
Antibiotic Stewardship 
According to the Association for Professionals in Infection Control and 
Epidemiology (APIC, 2012) antimicrobial stewardship is “a coordinated program that 
promotes the appropriate use of antimicrobials (including antibiotics), improves patient 
outcomes, reduces microbial resistance, and decreases in the spread of infections caused 
by multidrug-resistant organisms.” The consequential warnings of future inappropriate 
utilization of antibiotics were hinted at in 1945 by Sir Alexander Fleming during his 
Nobel Prize acceptance speech (Fleming, 1945). The Center for Disease Dynamics,   
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Economics & Policy (CDDEP, 2014) released global data for the third millenium that 
substantiates Dr. Fleming’s long-ago warning indicating that there has indeed been more 
than a 35% increase in antibiotic utilization between 2000 and 2010.   
Antibiotic stewardship priorities in the United States. The two leading 
concerns that present a challenge for healthcare-providers today as noted by Bjorkman, 
Berg, Viberg, and Lundborg (2013) are antibiotic resistance and UTIs. The United States 
is the third largest consumer of antibiotic prescriptions as evidenced by an unprecedented 
utilization increase. Hicks et al (2015) reported that 182.7 million prescriptions were 
provided to adult patients, or 789 prescriptions per 1000 adults according to U.S. 
ambulatory data from 2011 (p. 1311). Narrow-spectrum antibiotics (macrolides and 
penicillin’s) were prescribed for 41%, and broad-spectrum antibiotics prescribed for 31%, 
of females, >20 years of age, in ambulatory care settings (p. 1313). This represented a 
rate in antibiotic prescribing in females >20, of 1102.2 (prescriptions per 1000 persons) 
with an adjusted odds ratio (OR) of 2.4 (confidence interval (CI) 1.9-2.9) (Hicks et al., 
2015, p. 1313). By 2013, broad-spectrum antibiotic prescribing in adults increased from 
24% to 48% (Lee et al., 2014). Social determinants (2015, p. 1314) were recommended 
for future research.  
The U.S. female population literature gap. The management of urinary tract 
infections (UTIs) caused by antibiotic resistance in female populations is a challenging 
responsibility for any healthcare-provider (Pronovost, 2013). The influence on health care 
management in female populations begins before health problems occur (DeMilto & 
Nakashian, 2016). U.S. studies to date related to UTIs and antibiotic utilization have only   
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focused on pregnant female populations and the management of UTIs. This has been 
primarily due to the elevated risk of harm to the unborn child. Influential studies in the 
U.S. on social determinants such as income and gender and the role that these play in 
antibiotic resistance are absent.  
Studies conducted in the United States with antibiotic prescribing have 
determined that females are a high risk for resistant UTIs (Lawal, 2012; Vasudevan, 
2014). This evidence is directly related to ambulatory care visits for UTI symptoms and 
higher antibiotic utilization rates with both narrow and broad-spectrum antibiotics. 
Females comprise 84.5% of the 3 million patients in the United States with UTI 
symptoms as their primary complaint and are a high risk for UTIs (Thoureen, Scott, & 
Best, 2015). The rate of uncomplicated UTIs in females between the ages of 18-49 in the 
United States who receive antibiotic treatment is 28.2 percent for every 10,000 females 
(Lawal, 2012). The current gap in the literature is to understand how two classes of 
antibiotics (narrow and broad-spectrum) are prescribed to nonpregnant females with UTI 
symptoms in ambulatory care settings and the role in antibiotic-resistant UTIs. Without 
research studies conducted at home in the United States, barriers will remain unknown 
and funding cannot be substantiated. Unfortunately, economic study evidence outside of 
the U.S. is not comparable. 
UTI-specific antibiotic stewardship. Antibiotic stewardship in UTIs has become 
increasingly important. E. coli bacteria is the cause of 80% of every 7 million human 
UTIs diagnosed in the ambulatory care setting (Yadav, Singh, Kumar, Katewa, & 
Kumari, 2014; E. coli 131, a highly resistant strain of E. coli bacteria, is said to be   
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causing a “stealth pandemic” (Brusch, 2016). Recurrence in UTIs is usually related to the 
same pathogen that caused the initial infection. Antibiotic resistance and the overuse of 
broad-spectrum antibiotics have been noted as primary contributors in the escalation of 
antibiotic resistance and recurrence of UTIs outside of the United States (Zowawi et al., 
2015). Mazulli (2012) documented that a relapse in a UTI will occur in 25% of women 
within 6 months of treatment, therefore working towards a cure while limiting unintended 
consequences such as infection recurrence is the primary goal of antibiotic stewardship 
(Abbo & Hooten, 2014).  
 Bacterial strain resistance according to Abbo and Hooten (2014) that have been 
due to E. coli bacteria, prompted researchers to begin really studying antibiotic resistance 
and stewardship in ambulatory care settings just after the turn of the 21st century. It has 
been well documented that resistant endemic strains of bacteria and viruses are carried 
into the hospital setting from the community (Sydnor & Perl, 2011); the community-
acquired resistant strain of Staphylococcus aureus known as “CA-MRSA” is now present 
in hospital infections (p. 148). In 2015, a report to the President of the United States was 
provided to the White House that provided evidence of dire outcomes if antibiotic 
stewardship was not made a priority (President’s Council of Advisors on Science and 
Technology [PCAST], 2015). Ambulatory care has made great strides in the stewardship 
of appropriate prescribing practices as evidenced by studies published recently in the 
literature (Hicks et al., 2015). It is of great importance as antibiotic stewardship practices 
advance in ambulatory settings, especially with UTI treatment, that prescribing practices 
are continually re-evaluated at regular intervals (Abbo & Hooten, 2014).   
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Health-care providers utilize laboratory tests in the diagnosis, treatment, and 
continuing management of any illness. According to Bhavsar (2015), clinical significance 
is not often found among the many urinary cultures that a laboratory receives for testing. 
This is usually because of contamination that occurs during collection or other factors 
related to storage and transportation of urine specimens (Bekeris, Jones, Walsh, & 
Wagar, 2008). It is for these reasons that signs and symptoms must be considered and 
prescribing choices will need to be based solely on these details (Pallett & Hand, 2010). 
Unfortunately, this leads to prescribing antibiotics in a blind fashion, or “empirically.” 
Prescribing antibiotics empirically is a delicate act of balance that the healthcare- 
provider must go through to decide on the best course of treatment for their patient; this 
must be carried out rationally and thoughtfully. Choosing an antibiotic will need to be 
individualized for the patient and the geographic prescribing region. Consideration taken 
in advance for known epidemiologically significant pathogens in the area, especially 
those on the urgent or serious list of resistances (CDC, 2015c) may be the difference 
between curing illness and increasing the likelihood of recurrence. (Ventola, 2015). 
Patient factors to consider would be related to allergies, compliance with medications (if 
known), and costs that may be associated with treatment.  
Patients having a lower income status may not have the financial means to pay for 
more than basic testing or generic medications (Farfan-Portet, Van de Voorde, Vijens, & 
Stichele, 2012). Recurrent infections may be costlier due to that they may need longer   
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treatment or medications that are not available on a generic formulary list. Patients with a 
lower income may also add to the already-present antibiotic stewardship challenges that a 
healthcare-provider has in treating UTIs that are not associated with monetary costs. 
Current infection status, for example, may be unknown. The health-care provider may 
not get an accurate history and unable to discern whether the patient had already been 
treated for an infection. Poverty is also a known driving factor in medication sharing, 
hoarding of medications, and resorting to self-directed treatment (Planta, 2007). In 
today’s world, the internet is a place that can be unregulated when it comes to 
medications, which comes with its own challenges for antibiotic stewardship. Anyone 
can order almost any medication online and get it shipped directly to them, often without 
a prescription (Orizio, Merla, Schulz, & Gelatti, 2011). Computers may not even be 
necessary if you have a smartphone with an internet connection. If you do not have a 
phone with this technology, the public library has computers that are free for community 
residents to use (Gates Foundation, 2005). The public may be naïve about the lack of 
quality control with these medications available through the internet (World Health 
Organization [WHO], 2011).  
Other avenues to gain prescriptions that are not regulated are also available and 
are not difficult to come by if you have a passport and like to travel. In contrast, before 
the last two decades, internet services were not available and travel outside of the United 
States was not commonplace for the everyday resident. Cheap air travel today has 
afforded many the opportunity to travel to countries outside of the United States which 
have pharmacies that carry all types of medications including many antibiotics that do  
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 not require prescriptions signed by a provider (Lior & Cots, 2009). The real issue, 
however, lies in the absence of quality control measures. Medications that have not been 
checked for quality may pose further health and safety risks (WHO, 2011). According to 
a Princeton University (1995) publication, in using unregulated antibiotics, old 
antibiotics, or someone else’s antibiotics, a person will be compounding the already 
difficult task that any licensed healthcare-provider has in trying to cure an often-
uncomplicated illness like a UTI.  
Past and Present Dynamics with UTI Epidemiology 
 The historical literature reviewed indicates that prior to 1980, UTI antibiotic 
resistance was being seen in almost every antibiotic (Bartlett et al., 2011). Resistance 
patterns vary from region to region. Surveillance data that is normally performed at the 
local level (Masterton, 2008), to include state syndromic surveillance data captured via 
emergency departments, is often relied upon to determine antibiotic susceptibility in the 
community since there can be a large variance seen from region to region. Broad-
spectrum antibiotics are known to be the most corrupt out of all the antibiotics; their 
utilization is greater, therefore, resistant pathogens are also increased (Garau et al., 2014). 
Of the broad-spectrum antibiotic choices available today, several disturb normal flora, 
creating an environment for disease and resistant pathogens to flourish (Odonkor & 
Addo, 2011) and are known to have a higher risk for resistance such as sulfonamides, 
fluoroquinolones, and cephalosporins (Fair & Tor, 2014). The pathogen most likely to be 
the cause of up to 90% of UTIs in females are Escherichia coli (Gupta, Hooton, & 
Stamm, 2001; Ulleryd, 2003). Empiric selection of antibiotics has become more   
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important in recent times due to the increase in antibiotic resistance in E. coli. (2001). 
While previous surveillance studies may have identified significant differences in the 
frequency of susceptibility to common urinary anti-infectives between isolates collected 
from male and female patients, currently this has not been consistently observed (Lagace-
Wiens et al., 2011). This quantitative study’s aim was to investigate the temporal 
progression of antibiotic resistance incidence in UTIs and consider essential data details 
like the differences in economic status. 
Summary and Conclusions 
This chapter provided a literature review of historical, epidemiological, and 
fundamental knowledge concerning UTIs and antibiotic resistance. Empiric prescribing 
of broad-spectrum/narrow-spectrum antibiotics were also described which included those 
elements for antibiotic decision-making by the healthcare-provider. Clearly visible in the 
literature was the obvious contributory role of antibiotic exposure to urinary traction 
infection resistance. Additionally, the sample population attributes, independent and 
dependent variables, and suspected link of an increase in recurrent UTIs was exposed by 
the literature review. Unfortunately, studies that could be utilized to statistically 
investigate and reinforce an association between antibiotic resistance and urinary tract 
infections due to those risks such as health care coverage type, in nonpregnant low-
income female populations in U.S. ambulatory care settings, came up short without 
appropriate comparison of literature, or, did not exist at all. However, those documents in 
the literature reviewed could support the hypotheses and analysis of the dependent and 
independent variables. I will include a simplified description of data details, including   
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variables, to be assembled. The method and design proposed for this research study will 
be examined in Chapter 3.  
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Chapter 3: Research Method 
Researchers with the NAMCS began data collection in 1973, and, since 1989, 
have been collecting survey data annually in ambulatory physician clinics in the United 
States. I analyzed these survey data to evaluate risk factors for antibiotic resistance, with 
a specific focus on exposures to health care insurance coverage in low-income 
nonpregnant female populations with UTI symptoms who seek care in the ambulatory 
setting. Study subjects were drawn from 112 primary sampling units (PSUs) from 50 
states in the United States and the District of Columbia. I retrospectively reviewed the 
survey data to identify U.S. nonpregnant female populations who had sought care for UTI 
symptoms in ambulatory clinics and had health care coverage with Medicaid. In Chapter 
3, I describe the research methodology I used. I provide an overview of my research 
design, population, and sampling procedures; a description of study variables and my 
plan for data analysis; and discussion of threats to validity and ethical concerns.  
Research Design and Rationale 
In this study, I retrospectively illustrated and analyzed NAMCS observational 
data for a cohort of ambulatory care clinic visits by U.S. women.  The design facilitated 
discovery of important variables that were confounding factors whose relationships to the 
exposures were in question.  
Study Design Selection 
The design of a retrospective observational cohort study design was used to 
estimate antibiotic resistance in UTIs at the group level; ecological bias issues were   
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considered. I chose a retrospective approach based on the availability of variables during 
the original survey period chosen when antibiotic resistance is thought to occur (Al-Badir 
& Al-Shaikh, 2013). The NAMCS survey data available for public use were chosen from 
the years 2008-2012. The source population appropriate for this design was a cohort from 
U.S. ambulatory care nonpregnant female patient visits whose risk for UTI antibiotic 
resistance was due to exposure to poverty. Medicaid, a type of health care coverage was 
used to identify those with a lower income status. Risk adjustments were based on the 
NAMCS data collected from 2008-2012. The study design considered time, dose, and 
nature in the assignment of risks associated with UTI antibiotic resistance in the cohort 
chosen. The pursuit of a retrospective observational study seemed like a logical way to 
conduct this study investigation.  
Design advantages. The advantage to using a retrospective observational cohort 
study is that observer bias is lessened and multiple relationships to a single exposure can 
be investigated (Mann, 2003). Original survey data had already been procured by 
NAMCS, therefore, this design appeared to be the most efficient, least time-consuming, 
and most accurate analysis (see Euser, Zoccali, Jager, & Dekker, 2009; Huston & Naylor, 
1996). UTIs do not appear to be rare in the population of interest, low-income females. 
The observational design of this study allowed for access to health care survey 
information without having to conduct interviews; exposure association assumptions 
were made without direct observation (Carlson & Morrison, 2009). The data collection 
methodology for this study was completed using a standard method which allowed for  
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 comparison over time and generalization using multiple regions of the United States for 
analysis (see Mann, 2003).  
Study design disadvantages. Although bias is lessened with this study design, 
disadvantages in using this type of design are that causal relationships may be difficult to 
establish with more than one factor in use. Bias and confounding are difficult to control 
for (University of Portsmouth, 2012). The data I used were not designed specifically for 
my study which could have put me at a disadvantage. However, the survey data provided 
by NAMCS contained enough details for analysis. correctly for my examination. For 
example, it could have been difficult to identify a group to compare for exposure without 
specific age groups identified by NAMCS. However, this was not the case.  
Methodology  
Population and Sampling  
A secondary database source was utilized for my study which included 
information on the research design. I used the NAMCS database, a national sampling 
survey. The survey was designed and managed by the Ambulatory and Hospital Care 
Statistics branch of the CDC (2011). The sampling frame for 2008-2012 was composed 
of all nonfederal ambulatory care clinic visits to physician offices (excluding radiologists, 
pathologists, and anesthesiologists) whose provider data were maintained within the 
American Medical Association and American Osteopathic Association master file 
databases. The U.S. Census Bureau staff acted on behalf of the CDC in the collection of 
clinic visit data for the national ambulatory survey (Hall, Schwartzman, Zhang, & Liu, 
2017).  
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Sampling procedures. Sample visit data collected for NAMCS included 
physician and patient statistics, as well as patient visit characteristics. A three-stage 
process of sampling was conducted. Primary sampling units, or, “PSU’s,” were selected 
by NAMCS surveyors which consisted of first, 112 U.S. geographical regions, second, 
the selection of physician ambulatory clinics, and third, the selection of patient visits 
(CDC, 2011). Data processing and medical coding were performed by SRA International, 
Inc., Durham, North Carolina. Quality assurance and control procedures were performed 
with 10 percent of patient records used as a sample and were entered and coded 
individually (2011). Sample data formed standard errors and national estimates after 
estimated visit samples were weighted (2011). The CDC describes their calculations for 
each visit as complicated and had many stages designed for weight computations which 
reduced bias by inflating survey data or weighted national estimates (2001). A four-part 
activity was undergone for visit weighting that included “inflation by reciprocals of 
selection probabilities, adjustment for nonresponse, population ratio adjustments, and 
weight smoothing” (CDC, 2011). The complexity of their design was further explained 
by their use of Taylor approximations in SUDAAN to estimate the variability in sampling 
(2001).  
Study Population Sample 
The target source population for this research project consisted of National 
Ambulatory Medical Care Survey (NAMCS) patient visits occurring between 2008 and 
2012. Female patients, that visited U.S. ambulatory care clinics comprised 57% of the 
total patient visits in the NAMCS studies between years’ 2008-2012 (N=199,456). The   
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patient visit sample population that met inclusion criteria as high risk for developing 
antibiotic-resistant UTIs per the literature, were nonpregnant females, age 25-44, 
reporting to ambulatory care clinics for UTI symptoms, and on Medicaid (N=51).  
Sample methodology. All demographic and clinical patient visit data were 
reviewed for potential proximal and distal risk factors for exposure to potential negative 
outcomes. Proximal factors as explained by Krieger (2008) are those behavioral, 
biological, psychological, and physical processes that perform on or near the body and 
are controlled at an individual level. Distal risk factors, or those factors shaping a 
person’s exposure, may be stated as social determinants.  
Proximal risk factors for exposure and study inclusions. First, risk factors for 
proximal exposure were identified from the secondary sample frame population visit data 
that included the following variables (N=51): pregnancy status (nonpregnant), as 
evidenced by the NAMCS 2012 code “Pregnant” (2012) or ICD9 code classifications 
referent to a state of pregnancy for years’ 2008-2011; sex (female) as evidenced by 
“female;” age (25-44) as evidenced by “age 25-44;” “Diag1, 2, or 3” with ICD9 diagnosis 
codes of “5990” (urinary tract infection site not specified), or “5950” (acute cystitis), or 
“59080” (Pyelonephritis) (NAMCS, 2008; NAMCS, 2009, NAMCS, 2010, NAMCS, 
2011, NAMCS, 2012). Antibiotic prescribing methods by the provider, as a proximal 
factor for exposure, was identified at three levels (broad-spectrum antibiotics, narrow-
spectrum antibiotics, and the broad/narrow-spectrum combination of antibiotics). United 
States population identification for the purposes of this study may include “American” as 
a surrogate for U.S. nationality.   
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Distal risk factors for exposure and study inclusion. Distal factors structure a 
person’s exposure and in health care social determinants are influential, according to 
Krieger (2008). This study reviewed the secondary study data for exposure risk and found 
that a social determinant was available to include as an indicator of income status: 
Medicaid (N=51). Additionally, risk exposure related to evidence-based antibiotic 
treatment guidelines for uncomplicated and complicated UTIs in nonpregnant 
populations (National Institute for Health Care and Excellence [NICE], 2016) 
recommend a three-day course of antibiotics for uncomplicated UTIs and greater than 
three days if the UTI is complicated (recurrence, pyelonephritis). Antibiotic treatment 
status as a risk factor was available at two levels: initial, or continued.   
Sample exclusions. Those patient care visits and populations excluded in this 
study were phone visits, house calls, emergency department visits, federal facility visits, 
elderly adult, males, pregnant females, females under the age of 25 or over 44, pediatric, 
and hospitalized patient populations. Patient comorbidities were also not considered for 
risk now due to too many overall possibilities that would increase study length of time 
requirements and may have had an overall effect on the design choice. Those patients 
who were uninsured were additionally not included due to that the reason for not having 
insurance could not be ascertained. The NAMCS code for type of problem (new, chronic, 
post-op, etc.…), “MAJOR,” was also not utilized due to that the “reason for visit” 
(NAMCS, 2012) (RSV) had several choices, which did not correspond well with the type 
of problem.   
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Pregnant female-visit exclusion rationale. In chapter two it was noted that 
pregnant female UTI incidence was only slightly higher than non-pregnant female UTI 
incidence with variations between 2% and 13% (Lumbiganon, Laopaiboon, & 
Thinkhamrop, 2010; Matuszkiewicz-Rowynska, Malyszko, & Wieliczko, 2015). For this 
study, pregnant female patient visits were not included in the cohort age range selected 
because pregnant women are a much higher risk for complications due to their state of 
carrying an unborn child, and unlike nonpregnant females in the general population, 
pregnant females are screened for bacteriuria because of the high risk of pyelonephritis as 
a complication (August & DeRosa, 2012; Prakash & Saxena, 2013). All UTIs in 
pregnancy are considered complicated and normally only treated by a specialty health-
care provider. (Johnson & Kim, 2015).  
Cohort sample size. Logistic regression tables for sample size were reviewed to 
estimate the minimum sample size required to confidently accept the results of the 
analysis (Hsieh, 1989). The literature indicated that the probability of an antibiotic-
resistant UTI diagnosis within 6 months was 2, and one year after treatment was 3 (Al-
Badir & Al-Shaikh, 2013; Dason, Dason, & Kapoor, 2010). Countries other than the 
United States have begun publishing overall antibiotic resistance rates for various 
regions. Historically, the United States. had not published overall antibiotic resistance 
rates, though they have reported individual pathogen resistance rates. In 2011, this 
changed, and results produced from a survey conducted by the Infectious Disease Society 
of America Emerging Infections Network indicated that around “60% of participants had 
seen a pan-resistant, untreatable bacterial infection within the prior year” (Hersh,   
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Beekmann, Polgreen, Zaoutis, & Newland, 2009). For this study, which was based on a 
very large national survey, comprised of office visits, and from this, predominant factors 
already available as variables in the NAMCS data set were utilized to identify the sample 
frame that included exposures and non-exposures. These variables included “SEX” 
(1=Female); “PAYMCAID” (1= Medicaid as payment type); “PREGNANT” (2= 
Nonpregnant) (available only in 2012); “DIAG 1, 2, 3” (ICD 9 Codes indicating an upper 
or lower urinary tract infection), and, “AGE” (ages 25-44) (National Bureau of Economic 
Research [NBER], n.d.). From this overall exposure/non-exposure data, a simple random 
sample was calculated electronically for an appropriate sample size (National Statistical 
Service, n.d.). To find an odds ratio of 2.0 for a patient exhibiting UTI symptoms and 
having a positive UTI diagnosis, a one-tailed test was used with one standard deviation 
above the mean, a significance level of α= 0.05, confidence level of 95%, confidence 
interval of 0.05 (upper 0.55, lower 0.45), standard error of 0.03, relative standard error of 
5.10, and a power of 80%, indicating that a minimum of 42 cases were needed; 45 cases 
were randomly included for the final study sample.  
Variable Descriptions 
Variables collected for measurement purposes resulted from each ambulatory care 
visit captured by the national NAMCS survey data set between 2008 and 2012. Each visit 
was analyzed for possible associations related to the variables chosen for this study. The 
dependent and independent variable definitions and measurements are stated in Tables 1-
3, after the descriptions of all study variables.  
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Dependent variable.  The primary dependent variable (DV) identified was UTI 
antibiotic resistance (see Table 1). The variable was defined by ICD9 Diagnosis codes 
that included “5990 (UTI), 59780 (URETHRITIS), 5999 (URINARY DISORDER NOS), 
59080 (PYLONEPHRITIS), 5950 (ACUTE CYSTITIS), 5959 (CYSTITIS). 
Additionally, the variable was defined by utilizing the already present NAMCS 
codebooks available; “RFV” (reason for visit), included signs and symptoms of a UTI 
(NBER, n.d.). UTI signs and symptoms may be one of the following codes per NAMCS 
codebook (NBER, n.d.), “Reason for Visit Tabular Classification:” 1675 (urinary tract 
infection), 1660 (urinary dysfunction), 1650 (painful urination), 1910.1 (low back pain), 
1905 (back symptoms), 1545 (abdominal pain), 2705 (UTI pyelonephritis), 1665.1 & 
1665.2 (bladder pain and infection), 1645.0 (urinary urgency and frequency), 1545.2 (low 
abdominal or quadrant/inguinal pain),  1775 (pelvic pain), 10552 (flank pain) (2012), 
(AND) at LEAST ONE Antibiotic was Prescribed: “ABXRX: 1=Yes, 0=No, (AND) at 
LEAST ONE antibiotic must be new or continued.        
Measurement of the DV. The dependent variable in question was measured by 
whether it met definition criteria (1=UTI Resistance Criteria Met, and, (0=UTI 
Resistance Criteria Not Met).  
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Table 1 
 
Summary of Dependent Variable  
Variable type  Variable  Variable 
definition 
Coded value  Measure  Measure 
Dependent UTI 
Antibiotic 
Resistance 
1. An ICD9 
Diagnosis 
code of 
“5990, 59780, 
5999, 59080, 
5939,5950, 
5959.” 
 
UAR “1” = UTI 
Resistance 
Criteria Met   
 
“0” = UTI 
Resistance 
Criteria Not 
Met  
   
and/or 
 
   
  2. RFV (reason 
for visit) 
includes signs 
and symptoms 
of a UTI. UTI 
signs and 
symptoms may 
be one of the 
codes per 
NAMCS 
codebook: 
“Reason for 
Visit Tabular 
Classification.” 
See Table 2 for 
NAMCS codes 
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Table 2 
NAMCS Codes: Reason for Tabular Classification 
Code  
 
Code description 
 
1545 
 
 
Abdominal pain  
1545.2 
 
Lower abdominal or quadrant/inguinal pain 
1645.0 
 
Urinary urgency and frequency  
1650 
 
Painful urination  
1660 
 
Urinary dysfunction 
1665.1 & 1665.2 
 
Bladder pain and infection  
1675 
 
Urinary tract infection  
1775 
 
Pelvic pain 
1905 
 
Back symptoms 
1910.1 
 
Low back pain 
2705 
 
UTI pyelonephritis 
Note. The NAMCS codes, reasons for tabular classification, have been extracted from the NAMCS 
microdata file documentation for NAMCS survey years’ 2008-2012.  
 
 
Independent variables. The independent variables (IV) chosen were relevant to 
the study questions and hypotheses stated.  
IV initial antibiotics prescribed. The first IV, “initial antibiotics prescribed,” was 
coded as “INABXRX.” This variable was defined as a new patient visit related to UTI  
signs/symptoms with onset less than 3 months, (AND) one or more initial antibiotics 
prescribed. See Table 2.   
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Measurement of INABXRX. INABXRX was measured by “1=Initial Antibiotics 
Prescribed, and, 0=Initial Antibiotics Not Prescribed.” 
IV continued antibiotics prescribed. The second IV, “continued antibiotics 
prescribed,” coded as “CONABXRX.” CONABXRX was defined as a recurrent visit, by 
a referral or previously seen by a primary provider related to UTI signs/symptoms with 
onset less than 12 months, (AND) one or more antibiotics prescribed are continued. See 
Table 3.  
Measurement of CONABXRX. CONABXRX was measured as “1=Continued 
Antibiotics Prescribed, and, 0=Continued Antibiotics Not Prescribed.  
IV broad-spectrum antibiotics. The third IV, and first antibiotic class of IV’s of 
“broad-spectrum antibiotics,” coded as “BS,” was defined as a class of antibiotics that 
covers a variety of different pathogens in the treatment of an infection. Antibiotics 
selected for this study, including NAMCS codes (NBER, n.d.) were Sulfamethoxazole 
(29840), Metronidazole (19233), Levofloxacin/Levaquin (97163, 97045), 
Tindamycin/Tindazole (7212), Ciprofloxacin (92111/6839), Besifloxacin (11096), 
Ceftriaxone/Rocephin (91069), Azithromycin (93214), Keflex/Cephalexin (16475), 
Ampicillin (1685), Cefpodoxime (93166/d0095), Fluoroquinolones (8574), Doxycycline 
(10355), Augmentin/Amoxicillin-Clavulanate (60115), and Ceftizoxime (d00010) 
(NAMCS, 2012).  See Table 3. 
Measurement of BS. BS was measured “1=Broad-Spectrum Antibiotics 
Prescribed, and, 0=Broad-Spectrum Antibiotics Not Prescribed.”  
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IV narrow-spectrum antibiotics. The fourth IV and second antibiotic class of 
IV’s of “narrow-spectrum antibiotics” was coded as “NS.” NS was defined as antibiotics 
that target specific pathogens. Antibiotics selected for this study, including NAMCS 
codes (n.d.) were Clindamycin/Cleocin (6920/6905), 
Macrobid/Nitrofurantoin/Macrodantin (93090/18130), and Trimethoprim (32438). See 
Table 3.  
Measurement of NS. NS was measured as “1=Narrow-Spectrum Antibiotics 
Prescribed, and, 0=Narrow-Spectrum Antibiotics Not Prescribed.” 
IV broad- and narrow-spectrum antibiotics. The final antibiotic class of IV’s of 
“broad- and narrow-spectrum antibiotics” was coded as “BSNS.” BSNS was defined as 
either having both broad- and narrow-spectrum antibiotics prescribed during one visit, or, 
one medication that has a combined chemical combination of a broad-spectrum and a 
narrow-spectrum antibiotic. Antibiotics selected for this study, including their relevance 
NAMCS codes (n.d.) were Bactrim/Trimethoprim-Sulfamethoxazole 
(32423/3430/1017/29843). See Table 3.  
Measurement of BSNS. BSNS was measured as “1=Broad- and Narrow-spectrum 
Antibiotics Prescribed, and, 0=Broad- and Narrow-spectrum Antibiotics Not Prescribed.”  
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Table 3 
Summary of Independent Variables and Antibiotic Classes Prescribed 
Variable type Variable  Variable 
description  
Coded value  Measure  Measure 
Independent  Initial 
Antibiotics 
Prescribed  
1. A new patient 
visit related to 
UTI 
signs/symptoms 
with onset less 
than 3 months 
INABXRX “1” = Initial 
Antibiotic 
Prescribed 
Meets 
Defined 
Criteria 
“0” = Initial 
Antibiotic 
Prescribed 
Does Not 
Meet Defined 
Criteria  
  And    
  2. One or More 
initial 
antibiotics 
were 
prescribed  
   
Independent  Continued 
Antibiotics 
Prescribed  
1. Recurrent visit 
via referral or 
previously 
seen by 
primary 
provider 
related to UTI 
with onset less 
than 12 
months 
CONABXRX “1” = 
Continued 
Antibiotics 
Prescribed 
Meets 
Defined 
Criteria  
“0” = 
Continued 
Antibiotics 
Prescribed 
Does Not 
Meet Defined 
Criteria   
  And    
  2. One or more 
antibiotics 
prescribed are 
continued 
 
   
Independent Narrow-
Spectrum 
Antibiotics 
Class of 
Antibiotics that 
targets specific 
pathogens in the 
treatment of an 
infection 
NS “1” = 
Narrow-
Spectrum 
Antibiotic 
Prescribed 
Meets 
Defined 
Criteria 
“0” = 
Narrow-
Spectrum 
Antibiotic 
Prescribed 
Does Not 
Meet Defined 
Criteria  
Independent  Combined 
Broad & 
Narrow-
Spectrum 
Antibiotics 
1. Prescribed Both 
Broad & 
Narrow-
Spectrum 
Antibiotics at 
the same visit  
BSNS  “1” = Broad 
& Narrow-
Spectrum 
Antibiotics 
Prescribed 
Meets 
Defined 
Criteria 
“0” = Broad 
& Narrow-
Spectrum 
Antibiotics 
Prescribed 
Does Not 
Meet Defined 
Criteria  
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Antibiotic class relevance. The relevance of these two classes of antibiotics is that 
they include most all classes of antibiotics that are currently used in the U.S. to treat  
infections (Ventola, 2015), and implicated in the progression of antibiotic-resistant UTIs 
(Pallett & Hand, 2010; Bartlett, 2011). This study had included all broad- and narrow-
spectrum antibiotics available in the study data. Studies indicate that providers have been 
prescribing both broad-spectrum and other antibiotic classes simultaneously for the initial 
treatment of UTIs (Leekha, Terrell, & Edson, 2011). This method has been questioned as  
it is deemed an inappropriate way to practice prescribing antibiotics (Karam, Chastre, 
Wilcox, & Vincent, 2016) and has negative consequences documented with 
epidemiologically important gram-negative pathogens in UTIs (Nienhouse, 2014).  
Gram-positive bacteria such as Methicillin-resistant Staphylococcus aureus 
(MRSA), is also of epidemiological importance, however, gram-negative pathogens are 
tougher to treat (Soto, 2014). The literature has evidenced that most complaints about 
“UTIs” are that the cultures do not grow substantial amounts of bacteria and yet 
antibiotics are prescribed without an appropriate indication (2010). A cost-effective 
alternative to antibiotics has been documented in the literature as a simple urinalysis test, 
or “UA” (Brusch & Bronze, 2015). To demonstrate the impact, Al-Badir & Shaikh 
(2013) discussed that asymptomatic bacteriuria accounts for about 8% of health care 
visits where more than 25% of antibiotics are prescribed but rarely ever indicated 
(Shapiro, 2013). Shapiro et al. (2013) noted that 61% of antibiotics prescribed during 
ambulatory care visits broad-spectrum antibiotics and of these, macrolides, quinolones, 
and aminopenicillins accounted for between 12 and 25% of all antibiotics prescribed.   
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IV Ages. The IV of ages were coded as “AGES.” AGES were defined as those 
visits whose ages were between 25-44. See Table 4. 
Measurement of AGES.  AGES were measured as “1 = 25-29, 2 = 30-34, 3 = 35-
39, and 4 = 40-44.”  
IV Region. The IV of region was codes as “REGION.” REGIONS were defined 
as those regions of the United States that were included in the NAMCS surveys.  
Measurement of REGION.  REGION was measured as “1 = Northeast, 2 = 
Midwest, 3 = South, and 4 = West.” See Table 4.  
 
Table 4 
 
Summary of Independent Variables of Region and Ages 
 
Variable type Variable  Variable 
description 
Coded value Measure 
Independent  Ages  Includes ages 
25-44  
AGES  1 = 25-29 
2 = 30-34 
3 = 35-39 
4 = 40-44 
 
Independent Regions Includes the 
four major 
regions that 
NAMCS 
collected data 
from in the 
United States: 
Northwest, 
Midwest, 
South, and 
West   
REGION 1 = Northeast 
2 = Midwest 
3 = South  
4 = West 
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Data Analysis Plan 
 
Data Selection 
Data selected for analysis were abstracted from NAMCS datasets and summary 
tables from the CDC website for the survey (2014). The analysis included my study 
period of 2008-2012; years’ 2013-2015 were not utilized due to that the data was not 
publicly available when my study was designed (CDC, 2015a). The dependent and 
independent variable data abstracted from the national data set included for analysis was 
first done with Excel via a comma separated value (CSV) file that was already prepared 
for use on the NAMCS website. NAMCS data sets utilized are public, secure, and web-
based with Centers for Disease Control & Prevention (CDC) ownership and management 
of this data (CDC, 2014). The CSV file was scrubbed and recoded to include only 
relevant data elements for this study. SPSS, version 23, was utilized for the cohort 
analysis measures of exposures and outcomes. Many of the original code labels in the 
CSV file were changed for this study so that they were easily identifiable.  
The NAMCS public database did not include patient identifiers, therefore it was 
not necessary to replace patient identity with coding. The independent and dependent 
variables were either pre-assigned data codes, or I had assigned data codes for analysis. 
Variances can be produced according to NCHS (2015) by using a generalized variance 
curve which is discussed in the public-use file literature (2015).   
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Statistical Testing 
 Testing for logistic regression was carried out in SPSS to examine whether the 
independent variables of initial antibiotics prescribed, continued antibiotics prescribed, or 
broad, narrow, and broad- and narrow-spectrum-combined antibiotics predicted the DV, 
UTI antibiotic resistance. To assess variability on the dependent variable, the independent 
variables as predictors utilized the Nagelkerke R2. Cross tabs were executed to examine 
the association between DV and IV’s, along with Fisher’s Exact Test; Fisher’s will be 
utilized for analysis due to the small sample. Binary Logistic regression was executed for 
initial and continuous antibiotic prescribing, and also the classes of antibiotics included 
(broad, narrow, and combined broad- and narrow-spectrum) to illustrate the overall 
relationships of the IV’s significance for logistic regression.  
To assess individual predictors and the model fit, Hosmer-Lemeshow and Wald 
were applied to test the null hypothesis. Classification utilized for the variables and 
evidenced with a contingency table were: “Expected” (Exp), for the null, which is also 
written as the number of cases predicted (indicated by 0 or 1) divided by “Observed” 
(OBS), or the number counted. The odds ratio, or in binary regression known as Exp(B), 
was analyzed to determine event occurrence probability predictions. Significance was 
analyzed by using .05, and was identified as significant, >1 will; a 95% CI was 
additionally included for analysis. The greater the significance of each independent 
variable over 1.0, the more likely there will be for a risk with UTI antibiotic resistance. 
Omnibus testing was conducted to test the intercept-only with the fitted model using Chi-
square; p-values were interpreted.   
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Many of the restrictions placed on assumptions with linear regression are not an 
issue with logistic regression testing (Woltman, Feldstain, MacKay, & Rocci, 2012). A 
good example of this is that there were no assumptions made for equal variances, 
normality, or linearity as well as normal distribution was never assumed with an error 
term variance. The outcome (DV) was dichotomous and separate. With logistic 
regression, a large sample would have been optimal to use to achieve maximum likely 
outcomes, however, the sample size was ultimately small and was utilized to conduct 
analysis. I chose a public data file with a national sample that was very large and was 
hopeful that this would complement my use of discrete variables so that there was enough 
data to analyze each variable chosen.   
Research Question 1: Are initial antibiotics prescribed for UTIs associated with 
UTI antibiotic resistance?  
Ho1: There is no statistically significant association between antibiotic resistance 
in UTIs and initial antibiotics prescribed.  
Ha1: There is a statistically significant association between antibiotic resistance in 
UTIs related and initial antibiotics prescribed.  
Logistic regression was carried out to test the first hypothesis that there is no 
statistically significant relationship between continued antibiotics prescribed and UTI 
antibiotic resistance in nonpregnant females, age 25-44, on Medicaid, in U.S. ambulatory 
care settings. To test the hypothesis, the statistical significance used was a p-value of 
0.05. A p-value of <0.05 indicated rejection of the null hypothesis and failure to reject the 
alternative hypothesis. Prevalence rate will additionally be calculated.  
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Research Question 2: Are continued antibiotics prescribed for UTIs associated 
with UTI antibiotic resistance?  
Ho2: There is no statistically significant association between antibiotic resistance 
in UTIs and continued antibiotics prescribed.  
Ha2: There is a statistically significant association between antibiotic resistance in 
UTIs and continued antibiotics prescribed.  
Logistic regression was carried out to test the second hypothesis that there is no 
statistically significant relationship between continued antibiotics prescribed and UTI 
antibiotic resistance in nonpregnant females, age 25-44, on Medicaid, in U.S. ambulatory 
care settings. To test the hypothesis, the statistical significance used was a p-value of 
0.05. A p-value of <0.05 indicated rejection of the null hypothesis and failure to reject the 
alternative hypothesis. Prevalence rate will additionally be calculated. 
Research Question 3: Is the class of antibiotic prescribed for UTIs associated with 
UTI antibiotic resistance?  
Ho3: There is no statistically significant association between UTI antibiotic 
resistance and class of antibiotic prescribed.  
Ha3: There is a statistically significant association between UTI antibiotic 
resistance and class of antibiotic prescribed.  
Logistic regression was carried out to test the third hypothesis that there is no 
statistically significant difference in antibiotic resistance in UTIs in low-income 
nonpregnant females age 25-44 related and initial antibiotics prescribed. The dependent 
62 
 
variable was UTI antibiotic resistance. To test the hypothesis, the statistical significance 
used was a p-value of 0.05. A p-value of <0.05 indicated  
rejection of the null hypothesis and failure to reject the alternative hypothesis. Prevalence 
rate will additionally be calculated. 
Threats to Validity 
Data quality procedures for this study looked at those internal and external threats 
to validity that could occur and directly impact reliability and validity (Dyck, Culp, & 
Cacchione, 2007). Internal validity may likely be threatened from within the sample 
selected. The study sample chosen may not be representative of all females on Medicaid 
because disease likelihood would be related to racial and ethnic genetic traits; only black, 
white, and Hispanic or Latino, and “others” were utilized in the NAMCS study (2011; 
2012). Access to a more detailed account of patient characteristics was not available in 
the NAMCS public data sets.  
To increase the probability of patient characteristics, random selection will be 
utilized (Creswell, 2009). External validity threats occur when study results are applied to 
other populations (Steckler & McLeroy, 2008). The threat potentially lies with the fact 
that the primary study population was not federally-based ambulatory care facilities, and 
not inclusive of veterans, military ambulatory care, and outpatient public health clinics, 
emergency departments or acute care (emergency) department. Ambulatory care clinics 
that are federally funded, would be considered special populations a special and would 
not be generalizable. To manage this threat, study results would need to restrict those 
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patients who, in addition to receiving health care at non-federal ambulatory care facilities, 
including those ambulatory care clinics within a hospital facility, also receive health care  
at federal ambulatory care facilities such as the VA, military clinic, or public health 
clinic.   
Ethical Procedures 
This study was performed using a national, public secondary database, available 
on the internet via the CDC study website for the National Ambulatory Medical Center 
Survey (NAMCS). All patient data had been de-identified by the original surveyors prior 
to posting to the internet. The design variables according to the National Center for 
Health Statistics (NCHS), are confidential and have never been released to the public. 
Variances can be produced according to NCHS (2015) by using a generalized variance 
curve which is discussed in the public-use file literature (2015).  
According to NCHS (2015), the NAMCS is governed by Title 42, United States 
Code, and Section 242K, which permits data collection for health research. Title 42, 
United States Code, Section 242m (d) provides data confidentiality. The statistical 
purpose is the only reason that the survey data may be collected. “No information that 
could identify a person or establishment can be released to anyone, including the 
President, Congress, or any court, without the consent of the provider” (2015). The data 
must be protected according to many laws such as but not limited to the Privacy Act, and 
the Public Health Service Act; Census Bureau staff must sign a declaration of facts 
(2015). Healthcare-providers and patients can be confident that The NCHS and Census 
Bureau are protecting everyone’s privacy, as evidenced by a perfect record of privacy 
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protection (2015). The Walden University Internal Review Board (IRB) governs the 
handling of all study data; this study followed these procedures for collection and 
handling of the data.  
Summary 
For this study, an observational cohort, the retrospective approach was utilized to 
characterize the relationship between the dependent variable of UTI antibiotic-resistance 
incidence and the related independent variables of initial, continued, broad-spectrum, 
narrow-spectrum, and broad/narrow-spectrum antibiotics prescribed, to nonpregnant 
females, ages 25-44, on Medicaid who were seeking care for UTI symptoms in an 
ambulatory setting. The study purpose was to examine nonpregnant American female 
patients who were exposed to poverty and at risk for antibiotic resistance when seeking 
care for UTIs in ambulatory care settings. This was accomplished using secondary data 
from a cohort of U.S. ambulatory care facilities from large national surveys that are 
conducted annually in the United States by NAMCS, a branch of the Centers for Disease 
Control and Prevention (CDC) (NAMCS, 2008; 2009; 2010; 2011; 2012).  
Statistically significant relationship testing between the independent variables to 
understand why female low-income populations in ambulatory care are at risk for UTI 
antibiotic resistance was the basis for the data collection and analysis. Statistical analysis 
via binary logistic regression for the three hypotheses was completed. The next chapter, 
chapter 4, will detail the results of the analysis activities.  
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Chapter 4: Results 
The purpose of this study was to examine nonpregnant U.S. female patients who 
were exposed to poverty and at risk for UTI antibiotic resistance. The cohort was 
secondary data selected from a publicly-available data repository in the United States. 
This study investigated three key research questions. Research Question 1 (Are initial 
antibiotics prescribed for UTIs associated with UTI antibiotic resistance?) was designed 
to investigate whether the very first round of antibiotics prescribed for uncomplicated 
UTIs in nonpregnant females who had sought care in ambulatory settings might be 
contributing to antibiotic resistance.  
Very few studies in the United States about prescribing patterns of ambulatory 
care providers have been completed (Costelloe, Metcalfe, Lovering, Mant, & Hay, 2010; 
Wong et al., 2017). The first round of antibiotics is often prescribed empirically without a 
culture to prove what antibiotic is necessary to cure a UTI infection (Gibson & Toscano, 
2012). The duration and timing of antibiotic therapy has also been in question 
(Grigoryan, Zoorob, Wang, & Trautner, 2015). Research Question 2 (Are continued 
antibiotics prescribed for UTIs associated with UTI antibiotic resistance?) proposed that, 
when patients returned for care because of UTI symptoms that were not going away, the 
same or different antibiotics prescribed were contributing factors for antibiotic resistance. 
Research Question 3 (Is the class of antibiotics prescribed for UTIs associated with UTI 
antibiotics resistance?) was planned to capture the class of antibiotic that may have been 
contributing to initial or continued antibiotic prescribing and that may have been related 
to antibiotic resistance. It has been demonstrated that antibiotic guidelines and the actual   
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class of antibiotics used for UTIs in ambulatory care settings are disparate (Grigoryan et 
al., 2015). 
Data Collection 
Data sets, or, more specifically, CSV data file sets for the years 2008-2012) were 
downloaded from the National Bureau of Economic Research’s (NBER) website. This 
website is a national storage site for this type of data that contains research files in 
various formats as well as codebooks (National Bureau of Economic Research [NBER], 
n.d.). Data sets available on the NAMCS website did not include CSV-type files. 
However, SPSS-ready files were available. CSV-type data were selected for initial data 
abstraction and the scrub process. SPSS data files were also downloaded directly from the 
NAMCS webpages and compared to the NBER files for quality assurance.  
After the CSV files for Microsoft Excel from NBER were validated for 
completeness of data, each year’s worth of data was scrubbed to meet the ambulatory 
patient population criteria for my sample frame. These criteria included being female, 
between the ages of 25-44, and being a recipient of Medicaid. Criteria also included 
diagnoses variables. The sample frame also included nonpregnant women. Only the 2012 
data set included a new variable developed by NAMCS labeled “PREGNANT,” which 
identified a pregnant patient. Therefore, for years 2008-2011, NAMCS codes indicating a 
current pregnancy state, such as reason for visit (RSV), medications (MED), and ICD9 
codes for diagnosis (DIAG), were reviewed and scrubbed. Those cases that were 
identified as meeting criteria per codes for a positive current pregnancy status were 
deleted from the cohort sample. The data were further sorted to delete the multiple   
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extraneous variables that were present and would not be utilized by this study; this made 
the data more manageable. A separate Excel file was created in CSV format, and each 
year’s worth of scrubbed data was cut and pasted into this file to form one complete file 
for years’ 2008-2012.  
Case-Finding 
Initially, to ensure research standards with data were met, I reviewed all NAMCS 
and HAI definitions, then performed any necessary variable remodeling. NAMCS survey 
years 2008-2012 were reviewed. Regions used in the parent study (Northeast [1], 
Midwest [2], South [3], and West [4]), were noted as well as Ages 25-44. The first step 
involved using NAMCS’ study’s definitions and inserting dummy variables that would 
better serve the analysis. All variables were identified by the dependent variable (DV) 
definition were located: (diagnosis) “DIAG1, DIAG2, DIAG3,” (reason for visit) “RFV1, 
RFV2, RFV3,” (medication) “MED1-MED8,” and (new medication/continued 
medication) “NUMED, CONTMED.” The independent variables of NUMED and 
CONTMED represented both initial and continuous prescribing as well as prescribing in 
12 months or less.  
A new variable column labeled “UAR,” depicting dichotomous DV UTI 
resistance, was then inserted into the CSV data file used for this study. To properly have 
a defined DV (UAR), it was critical that all diagnoses, reasons for visit, and medications 
were reviewed with each year’s code book. Each case that met criteria was entered into 
the variable UAR as “1,” and, each case that did not meet criteria was entered in as “0.” 
All codes in each of these categories that were related to an acute urinary tract infection   
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(upper or lower) were reviewed and logged for UTI exposure relevance: the sample 
(n=45) met criteria for UTI exposure out of the sample frame (total nonpregnant female, 
ages 25-44, on Medicaid, and with a positive diagnosis/symptom of UTI (N=51). 
Subsequently, the Excel file with all case variables were exported and uploaded into 
SPSS for analysis.  
SPSS Variable View 
 Once the data were uploaded to SPSS, in “Variable View” (SPSS), each variable 
header was reconfigured to represent the variable type (numerical) to conduct analysis 
appropriately. Changes made in variable view:  labels were entered; values reflecting the 
outcome were input; missing data was reviewed and corrected if necessary; measure 
(ordinal/nominal/scale) was indicated.    
Sample Size 
As discussed in Chapter 3, simple random sampling calculation conducted 
electronically was executed by utilizing the total sample frame (N=51), a confidence level 
of 95%, a confidence interval of 0.05 (upper 0.55, lower 0.45), standard error of 0.03 
relative standard error of 5.10, and power of 80%. The results had indicated that a 
minimum sample size of 45 was necessary to perform this study. SPSS was utilized to 
perform random sampling; N=51 was input as criteria for the random sample. Probability 
sampling was utilized because it has been shown to provide better assurance that the 
sample is representative of the population (Omair, 2014).   
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Results 
The sample frame (N=51) was downloaded into SPSS version 23 from Microsoft 
Excel and a final sample of n=45 was produced. Descriptive statistics was utilized to 
summarize the demographic sample and antibiotics prescribed.  
Assumption Errors and Inquiry 
 Before  the investigation of this study’s research questions could begin, frequency 
distribution, errors, and assumptions were investigated in SPSS. To describe the 
interactions between two categorical IVs, crosstabs was utilized to create contingency 
tables. Frequency tables were also created for single categorical variables such as 
demographics (See Table 5), timing of antibiotics prescribed (initial or continued), and 
each class of antibiotics (broad-spectrum, narrow-spectrum, and combined broad- and 
narrow-spectrum (see Table 6).    
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Table 5 
 
Frequencies and Percentages for Sampled Population Age, Region, Visit Year, Visit 
Month, and Visit Day of the Week with Symptomatic UTI  
 
 
 
N  Percent 
(%) 
Age frequency and percentage with UTI symptoms 
     25-29 
     30-34 
     35-39 
     40-44 
 
 
15 
12 
9 
9 
 
33.2 
26.7 
20.0 
20.0 
Region frequency and percentage with UTI symptoms 
      Northeast 
      Midwest 
      South 
      West 
 
 
10 
7 
12 
11 
 
22.2 
15.6 
26.7 
24.4 
Year visit frequency and percentage with UTI symptoms 
      January 
February 
March 
April 
May 
June 
July 
August 
September 
October 
November 
December 
 
2 
3 
5 
6 
2 
3 
2 
2 
3 
5 
8 
4 
4.4 
6.7 
11.1 
13.3 
4.4 
6.7 
4.4 
4.4 
6.7 
11.1 
17.8 
8.9 
Day of the week visit frequency and percentage with UTI symptoms 
      Monday 
Tuesday  
Wednesday 
Thursday 
Friday  
 
 
12 
11 
9 
7 
5 
 
26.7 
24.4 
20.0 
15.6 
11.1 
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Table 6 
 
Frequency Distribution of Timing and Antibiotic Class Prescribing for UTI Symptoms 
 
 Frequency Percent 
 
               BS Antibiotics Not Prescribed                                                     
                
               BS Antibiotics Prescribed  
                
               Total  
 
               NS Antibiotics Not Prescribed                                                       
 
               NS Antibiotics Prescribed   
           
               Total  
 
              BSNS Antibiotics Not Prescribed                                                      
 
              BSNS Antibiotics Prescribed  
 
              Total  
 
               
 
 
 
21
 
24 
 
45 
 
29
 
16 
 
45 
 
38
 
7 
 
45 
 
 
 
 
46.7 
 
53.3 
 
100.0 
 
64.4 
 
35.6 
 
100.0 
 
84.4 
 
15.6 
 
100.0 
 
 
 
 
 
 
Summary Population Frequency Distribution  
          Of the 45 patients in the sample between the ages of 25-44, the average age of 
nonpregnant females on Medicaid was 33.  The age in this sample who visited 
ambulatory care the most were 25-29-year-olds (33.2%). The region that reported the 
most visits by nonpregnant ambulatory care patients were from the Southern region of 
the U.S (26.7%). Data concluded that nonpregnant females, ages 25-44, and on 
Medicaid, were also more likely to visit ambulatory care on a Monday (26.7%) during 
the month of November (17.8%). During the years utilized for this study, 2008-2012,   
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2009 received the most visits (40%) by the sample population in ambulatory care 
settings.   
Summary Antibiotic Timing and Class Frequency Distribution 
Next, frequency distributions of prescribing antibiotics were run on initial 
antibiotics prescribed (INABXRX) in 3 months or less for a symptomatic UTI (Figure 
1), and, continuous antibiotics prescribed (CONTABXRX) (Figures 2) in 12 months or 
less for a symptomatic UTI. Additionally, frequency tables were provided for those 
classes of antibiotics included in this study that were prescribed for a symptomatic UTI: 
broad-spectrum antibiotics prescribed (BS), narrow-spectrum antibiotics prescribed 
(NS), and combined broad & narrow-spectrum antibiotics prescribed (BSNS) (see Table 
3 and Figures 3, 4, 5). There appears to be a higher frequency (36%) of utilization with 
initial antibiotics prescribed than continued prescribing.  
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  Figure 1. Bar chart of Frequency of Initial Antibiotics Prescribed in 3 Months or Less. 
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Figure 2. Bar Chart of Frequency of Continued Antibiotics Prescribed in 12 Months or 
Less 
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Figure 3. Bar Chart of Frequency of Broad-Spectrum Antibiotics Prescribed  
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Figure 4. Bar Chart of Frequency of Narrow-Spectrum Antibiotics Prescribed  
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Figure 5. Bar Chart of Frequency of Combined Broad- and Narrow-Spectrum Antibiotics 
Prescribed  
 
 
Summary of Antibiotic Prescribing Frequency Distribution  
  Outcome evidence with antibiotic prescribing after frequency distributions were 
executed indicated that of the sample (n=45), nonpregnant females, ages 25-44, and on 
Medicaid(n=42), were likely to be prescribed initial antibiotics within 3 months 91% of 
the time. Those patients who returned to ambulatory care with recurrent symptoms 
(n=12), were only likely to have antibiotics continued 55.6% of the time. Patients (n=24) 
were more likely (53%) to be prescribed broad-spectrum antibiotics when seeking care in 
ambulatory clinics for UTIs compared to narrow-spectrum antibiotics, prescribed 18%   
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less frequently than broad-spectrum, and combined broad- and narrow-spectrum 
antibiotics, prescribed 38% less frequently than broad-spectrum antibiotics. Narrow-
spectrum antibiotics (n=16) were only prescribed 36% of the time, and combined broad- 
and narrow-spectrum antibiotics (n=7) were only prescribed 16% of the time.  
Research Question 1 
Research Question 1: Are initial antibiotics prescribed for UTIs associated with 
UTI antibiotic resistance?  
Ho1: There is no statistically significant association between antibiotic resistance 
in UTIs and initial antibiotics prescribed.  
Ha1: There is a statistically significant association between antibiotic resistance in 
UTIs and initial antibiotics prescribed.  
 To analyze research question 1, testing for an association, followed by binary 
regression and a review of predictor characteristics was executed.  
Association. 
To test for association between initial antibiotics prescribed (IV), and UTI 
antibiotic resistance (DV) crosstabulation was executed and analyzed. A contingency 
table was produced (see Table 7) to display variable counts and percentages. Due to the 
small sample size and violation of assumptions for Chi-Square testing, Fisher’s Exact test 
was reported. The proportion of those patients who were prescribed initial antibiotics in 3 
months or less that developed UTI antibiotic resistance (UAR) was 51.2%, or, 21 out of 
41 cases.    
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Table 7 
 
Initial Antibiotics Prescribed in 3 Months or Less and UTI Antibiotic Resistance 
 
 UTI 
Resistance 
Criteria Not 
Met  
UTI 
Resistance 
Criteria Met  
Total  
% Initial 
Antibiotics 
Not 
Prescribed in 
3 Months or 
Less 
 
 
 
25%  
 
 
75% 
 
 
100% 
% Initial 
Antibiotics 
Prescribed in 
3 Months or 
Less 
 
 
 
48.8% 
 
 
51.2% 
 
 
100% 
Table 7 Contingency Table  
 
It was noted that the results of Fisher’s Exact test (see Table 8) indicated that 
there was no statistically significant relationship observed between the exposure to initial 
antibiotics prescribed in 3 months or less and UTI antibiotic resistance in nonpregnant 
female patients, ages 25-44, on Medicaid, who presented to an ambulatory care clinic 
with UTI symptoms; the p-value was >.05 (p=.611) therefore I failed to reject the null 
hypothesis (see Table 8).  
Table 8 
 
Summary of Fisher’s Exact Test and Initial Antibiotics Prescribed  
 
 N 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Fisher's Exact Test  .611 .357 
 45   
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Binary logistic regression. Binary logistic regression was executed to analyze 
the risk of antibiotic resistance in UTIs in those patients who were prescribed antibiotics 
initially for UTI symptoms while controlling for AGES and REGION.  The results 
indicated that initial prescribing of antibiotics was not a statistically significant predictor 
of UTI antibiotic resistance within 3 months or less after the onset of UTI symptoms 
(p>.05). There was a large improvement with the inclusion of predictor variables and the 
model fit (X2=5.502(8), p=.703, Nagelkerke R2= .153). The final model, however 
indicated that AGES and REGION had very little effect on initial antibiotics prescribed 
(p= >.05). No further predictions were made thus I failed to reject the null hypothesis. 
The results of binary regression with initial antibiotics prescribed predicting UTI 
antibiotic resistance in 3 months or less can be reviewed in Table 9.   
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Table 9 
 
Summary of Binary Logistic Regression and Initial Antibiotics  
 
Variables 
 
B Sig. β 
INABAXRX 1.34 
 
.301 3.82 
AGES (1) -1.086 
 
.258 .338 
AGES (2) .248 
 
.813 1.28 
AGES (3) -.216 
 
.839 .806 
REGION (1) .077 
 
.950 1.080 
REGION (2) .570 
 
.558 1.77 
REGION (3) -.229 
 
.831 .795 
REGION (4) .783 
 
.380 2.19 
Notes. R2 = .153 (p>.05) 
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To examine the first binary logistic regression model, the Hosmer and Lemeshow 
test was processed along with a classification table to check for the model fit. Hosmer 
and Lemeshow indicated that there was a significant improvement between the observed 
data in block 0 and the final regression model, therefore this model appeared to be a good 
fit (>.05) for the data at an acceptable level (X2=2.594(7), p=.920). The results of the 
model summary concluded that between 11% and 15% of the variation in UTI antibiotic 
resistance was explained by the final model. The correct classification rate increased by 
13% (51.1 to 64.4.).  
A review of the variables in the equation were analyzed. The variable, initial 
antibiotics prescribed (INABXRX), did not appear to contribute to the model; initial 
antibiotics prescribed are not statistically significant (>.05, p= .301). The positive 
coefficient B indicated that the target group had more cases coded as “1” (initial 
antibiotics prescribed) than “0” (initial antibiotics not prescribed). Negative coefficients 
(B) for AGES (1) (25-29-year-olds), AGES (3) (35-39-year-olds), and REGION (3) 
(Southern United States) indicated that these groups had less cases coded as “1.” Age 
(AGES) and Region (REGION) overall were not significant. The coefficient (B) for 
initial antibiotics prescribed revealed that the odds of UTI antibiotic resistance was 1.340 
more likely for those prescribed initial antibiotics. The Sig. (.301) concluded that the chi 
square test for UTI antibiotic resistance versus initial antibiotics prescribed were not 
statistically significant, therefore I failed to reject the null hypothesis; data remains 
inconclusive because there is insufficient evidence at the alpha level of significance to 
reject the claim that initial antibiotics prescribed are related to UTI antibiotic resistance.   
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The odds for those patients who were prescribed initial antibiotics for symptomatic UTIs 
were 3.821 (95%CI .302 to 48.364) times more likely to have UTI antibiotic resistance in 
an ambulatory care setting when prescribed antibiotics initially for a UTI. Since the CI 
(confidence interval) spans 1.0, the increased odds (3.821) of UTI antibiotic resistance 
among nonpregnant females, ages 25-44, and on Medicaid, who were prescribed 
antibiotics initially for UTIs at baseline, does not reach statistical significance.  
Predictor characteristics. Predictor characteristics based on descriptive 
measures of prevalence and incidence, were calculated for initial antibiotics and UTI 
antibiotic resistance (see Table 10). The prevalence of UTI antibiotic resistance in the 
total number of sample cases with UTI antibiotic resistance (n=45) was 9% when 
prescribed initial antibiotics. The incidence rate (new cases of antibiotic resistant UTIs) 
for those at risk in 3 months or less was 7%. 
Table 10  
 
Predictor Characteristics of Initial Antibiotics Prescribed  
 
 Prevalence Incidence  
Initial  
Antibiotics Prescribed   
 
 
9% 
 
7% 
 
 
Research Question 2 
Research Question 2: Are continued antibiotics prescribed for UTIs associated 
with UTI antibiotic resistance?  
Ho2: There is no statistically significant association between antibiotic resistance 
in UTIs and continued antibiotics prescribed.  
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Ha2: There is a statistically significant association between antibiotic resistance in 
UTIs and continued antibiotics prescribed.  
 To analyze research question 2, testing for an association, followed by binary 
regression and a review of predictor characteristics was executed.   
Association.  
 
To test for association between continued antibiotics prescribed (IV), and UTI 
antibiotic resistance (DV) crosstabulation was executed and analyzed. A contingency 
table was produced (see Table 11) to display variable counts and percentages. Due to the 
small sample size and violation of assumptions for Chi-Square testing, Fisher’s Exact test 
was reported. The proportion of those patients who were prescribed continued antibiotics 
for recurrent UTIs in 12 months or less who developed UAR was 84.6%, or, 22 out of 26 
cases (see table 11). 
Table 11 
 
Continued Antibiotics Prescribed in 12 Months or Less and UTI Antibiotic Resistance 
 
  UTI 
Resistance 
Criteria Not 
Met  
 UTI 
Resistance 
Criteria Met  
Total  
% Continued  
Antibiotics 
Not 
Prescribed in 
12 Months or 
Less 
 
 
 
94.7%  
 
 
5.3% 
 
 
100% 
% Continued 
Antibiotics 
Prescribed in 
12 Months or 
Less 
 
 
 
15.4% 
 
 
84.6% 
 
 
100% 
Table 11 Contingency Table  
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Fisher’s Exact test (see Table 12) evidenced a statistically significant relationship 
observed between the exposure to continued antibiotics prescribed in 12 months or less 
and UTI antibiotic resistance in nonpregnant female patients, ages 25-44, on Medicaid, 
who presented to an ambulatory care clinic with UTI symptoms; the p-value was <.05 
(p=.000) therefore the null hypothesis was rejected (see Table 12).  
 
Table 12 
 
Summary of Fisher’s Exact Test and Continued Antibiotics Prescribed  
 n 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Fisher's Exact Test  .000 .000 
 45   
 
Binary logistic regression. Binary logistic regression was executed to analyze 
the risk of antibiotic resistance in UTIs in those patients whose antibiotics were continued 
for UTI symptoms while controlling for AGES and REGION.  The results indicated that 
continued prescribing of antibiotics was not a statistically significant predictor of UTI 
antibiotic resistance within 12 months or less after the onset of UTI symptoms (p>.05). 
There was an improvement for fit with the inclusion of the variables (X2=42.098, p=.000, 
Nagelkerke R2= .810). The final model, however, indicated that the inclusions of AGES 
and REGION had very little associated with continued antibiotics prescribed. No further 
predictions were made, thus I failed to reject the null hypothesis. The results of binary 
regression with continued antibiotics prescribed predicting UTI antibiotic resistance in 12 
months or less can be reviewed in Table 13.   
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Table 13  
 
Summary of Binary Logistic Regression and Continued Antibiotics  
 
Variables 
 
B Sig. β 
CONABAXRX -55.26 
 
.997 .000 
AGES (1) -18.73 
 
.998 .000 
AGES (2) -17.39 
 
.998 .000 
AGES (3) 34.67 
 
.997 1.138E+15 
REGION (1) -1.03 
 
.579 .358 
REGION (2) -.231 
 
.899 .794 
REGION (3) 17.26 
 
.998 31465879.291 
REGION (4) .-.427 
 
.780 .653 
Notes. R2 = .810 (p>.05) 
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To examine the second binary logistic regression model, the Hosmer and 
Lemeshow test was processed along with a classification table to check for the model fit. 
Hosmer and Lemeshow indicated that there was a significant improvement between the 
observed data in block 0 and the final regression model, therefore this model appeared to 
be a good fit (>.05) for the data at an acceptable level (X2=1.201(6), p=.977). The results 
of the model summary concluded that between 60% and 80% of the variation in UTI 
antibiotic resistance was explained by the final model. The correct classification rate 
increased by 38% (51.1 to 88.9.).  
A review of the variables in the equation were analyzed. The variable, continued 
antibiotics prescribed (CONABXRX), did not appear to contribute to the model; 
continued antibiotics prescribed were not statistically significant (>.05, p= .997). The 
negative coefficient B indicated that the target group had less cases coded as “1” 
(continued antibiotics prescribed) than “0” (continued antibiotics not prescribed), and 
was not significant after controlling for the other variables. Age (AGES) and Region 
(REGION) did not contribute to the model and were not significant. The coefficient (B) 
revealed that the odds of UTI antibiotic resistance was .000 more likely for those 
prescribed continued antibiotics. The Sig. (.997) concluded that continued antibiotics 
prescribed were not statistically significant, therefore I failed to reject the null hypothesis; 
data remains inconclusive because there is insufficient evidence at the alpha level of 
significance to reject the claim that the continuation of antibiotics prescribed are related 
to UTI antibiotic resistance The odds for  those patients who were prescribed continued 
antibiotics for symptomatic UTIs were .000 (95%CI .000 to .000) neither more or less   
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likely to have UTI antibiotic resistance in an ambulatory care setting when prescribed 
antibiotics initially for a UTI.  Since the CI (confidence interval) was 0, the increased 
odds (.000) of UTI antibiotic resistance among nonpregnant females, ages 25-44, and on 
Medicaid, who were continued on antibiotics prescribed for UTIs at baseline, did not 
explain any statistical significance.  
Predictor characteristics of continued antibiotics. Predictor characteristics 
based on descriptive measures of incidence and prevalence were calculated for continued 
antibiotics and UTI antibiotic resistance (see Table 14). The prevalence of UTI antibiotic 
resistance in the total number of sample cases with UTI antibiotic resistance (n=45) was 
51% when antibiotics prescribed were continued for recurrent UTIs. The incidence rate 
(new cases of antibiotic resistant UTIs) for those at risk in 12 months or less was 49%  
 
Table 14 
 
Predictor Characteristics of Continued Antibiotics Prescribed  
 
 Prevalence Incidence  
Continued  
Antibiotics Prescribed   
 
51% 
 
49% 
 
 
 
Research Question 3 
Research Question 3: Is the class of antibiotic prescribed for UTIs associated with 
UTI antibiotic resistance?  
Ho3: There is no statistically significant association between UTI antibiotic 
resistance and class of antibiotic prescribed.   
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Ha3: There is a statistically significant association between UTI antibiotic 
resistance and class of antibiotic prescribed.  
Association.  
 
To test for association between the various classes of antibiotics prescribed (IVs), 
and UTI antibiotic resistance (DV) crosstabulation was executed and analyzed, and 
predictor characteristics were discussed. A contingency table was produced (see Table 
15) to display variable counts and percentages. Due to the small sample size and violation 
of assumptions for Chi-Square testing, Fisher’s Exact test was reported. The proportion 
of those patients who were prescribed broad-spectrum antibiotics for symptomatic UTIs 
in 12 months or less and developed UAR was 79.2% (19 out of 24 patients); narrow-
spectrum antibiotic exposure associated with UTI antibiotic resistance was 31.3% (5 out 
of 16 patients); and an exposure to a combination of broad- and narrow-spectrum 
antibiotics was 57.1% (4 out of 7 patients) (see table 15). 
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Table 15  
Classes of Antibiotics Prescribed in 12 Months or Less and UTI Antibiotic Resistance 
 
 
Class of 
Antibiotics 
 UTI 
Resistance 
Criteria Not 
Met  
 UTI 
Resistance 
Criteria Met  
Total 
% Broad-
Spectrum 
Antibiotics 
Not 
Prescribed 
  
 
 
81.0%  
 
 
19.0% 
 
 
100% 
% Broad-
spectrum 
Antibiotics 
Prescribed  
 
 
 
20.8% 
 
 
79.2% 
 
 
100% 
% Narrow-
Spectrum 
Antibiotics 
Not 
Prescribed  
 
 
 
37.9% 
 
 
62.1% 
 
 
100% 
% Narrow-
Spectrum 
Antibiotics 
Prescribed  
 
 
 
68.8% 
 
 
31.3% 
 
 
100% 
% Combined 
Broad & 
Narrow-
Spectrum 
Antibiotics 
Not 
Prescribed  
 
 
 
 
50% 
 
 
 
50% 
 
 
 
100% 
% Combined 
Broad & 
Narrow-
Spectrum 
Antibiotics 
Prescribed  
 
 
 
 
42.9% 
 
 
 
57.1% 
 
 
 
100% 
Table 15 Contingency Table  
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The results of Fisher’s Exact test (see Table 16) did not indicate a statistically 
significant relationship (<.05) observed between an exposure with the broad-spectrum 
(.000) class of antibiotics prescribed in 12 months or less and UTI antibiotic resistance in 
nonpregnant female patients, ages 25-44, on Medicaid, who presented to an ambulatory 
care clinic with UTI symptoms. Thus, the null hypothesis was rejected for broad-
spectrum antibiotic prescribing.  There were, however, statistically significant 
relationships observed in both narrow-spectrum and combined broad- and narrow-
spectrum antibiotics prescribed (p>.05): .065 (NS); 1.00 (BSNS). Thus, I failed to reject 
the null hypotheses for narrow-spectrum and combined broad- and narrow-spectrum 
antibiotics (see Table 16).  
 
Table 16 
 
Summary of Fisher’s Exact Test and Classes of Antibiotics Prescribed 
 
       n Exact Sig. (2-Sided) Exact Sig. (1-Sided) 
Fisher’s Exact 
Test 
 
BSABX 
 
NSABX 
 
BSNSABX 
 
 
 
 
45 
 
45 
 
45 
 
 
 
.000 
 
.065 
 
1.00 
 
 
 
.000 
 
.047 
 
.526 
 
 
Binary logistic regression. Binary logistic regression was executed to analyze 
the risk of antibiotic resistance in UTIs in those patients exposed to three distinct classes 
of antibiotics (broad-spectrum, narrow-spectrum, and combined broad- and narrow-
spectrum), while controlling for ages (AGES, (1)25-29, (2)30-34, (3)35-39, (4)40-44), 
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region (REGIONS, (1) Northeast, (2) Midwest, (3) South, and (4) West), initial 
antibiotics prescribed (INABXRX), and continued antibiotics prescribed (CONABXRX). 
Coding of the variables BS, NS, and BSNS was indicated by “0=Broad/ Narrow/ 
Combined Broad- and narrow-spectrum antibiotics not prescribed,” and “1=Broad/ 
Narrow/ Combined Broad- and narrow-spectrum antibiotics prescribed.  
Broad-spectrum antibiotics and binary logistic regression. The results of Broad-
spectrum antibiotics as a predictor of UTI antibiotic resistance indicated that this was not 
a statistically significant predictor after the onset of UTI symptoms (p>.05). AGES, 
REGION, INITIAL, and CONTINUED were controlled for (R2.923 (10), p= 52.997). 
Thus, I failed to reject the null hypothesis. The results of binary regression with broad-
spectrum antibiotics prescribed predicting UTI antibiotic resistance in 12 months or less 
can be reviewed in Table 17.  
 
 
 
 
  
93 
 
Table 17 
 
Summary of Binary Logistic Regression and Broad-Spectrum Antibiotics  
 
Variables 
 
B Sig. β 
BS -70.11 
 
.995 .000 
AGES (1) -71.36 
 
.997 .000 
AGES (2) -51.49 
 
.999 .000 
AGES (3) 52.40 
 
.998 5.694E+22 
REGION (1) -18.28 
 
.996 .000 
REGION (2) 14.15 
 
1.00 1390232.41 
REGION (3) 15.43 
 
1.00 5024326.69 
REGION (4) 17.59 
 
.997 .000 
INABXRX 
 
-35.15 .995 .000 
CONABXRX 
 
-71.93 .995 .000 
Notes. R2 = .923 (p>.05) 
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To examine the third binary logistic regression model, the Hosmer and Lemeshow 
test was processed along with a classification table to check for the model fit. Hosmer 
and Lemeshow indicated that there was neither significant or insignificant improvement 
between the observed data in block 0 and the final regression model, therefore this model 
did not appear to be of a good fit (<.05) without an acceptable level (X2=.000(5), 
p=1.000). The results of the model summary concluded that between 69% (Cox & Snell 
R2)) and 92% (Nagelkerke R2) of the variation in UTI antibiotic resistance could be 
explained by the final model. The correct classification rate had increased by 42% (51.1 
to 93.3.).  
A review of the variables in the equation were analyzed. The variable, broad-
spectrum antibiotics prescribed (BS), did not appear to contribute to the model; broad-
spectrum antibiotics prescribed was not statistically significant (p>.05, p= .995). The 
negative coefficient B (-70.105) indicated that the target group had less cases coded as 
“1” (broad-spectrum antibiotics prescribed) than “0” (broad-spectrum antibiotics not 
prescribed), and was not significant after controlling for the other variables. Age (AGES), 
Region (REGION), initial antibiotics prescribed (INABXRX), and continued antibiotics 
prescribed (CONABXRX) did not contribute to the model and were not significant 
(p>.05). The coefficient (B) revealed that the odds of UTI antibiotic resistance was .000 
more likely for those prescribed broad-spectrum antibiotics. The Sig. (p>.05, .995) 
concluded that broad-spectrum antibiotics prescribed were not statistically significant, 
therefore I failed to reject the null hypothesis and data remains inconclusive because 
there is insufficient evidence at the alpha level of significance to reject the claim that   
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broad-spectrum antibiotics prescribed are related to UTI antibiotic resistance. The odds 
for those patients who were prescribed broad-spectrum antibiotics for symptomatic UTIs 
were .000 (95%CI .000 to .000) neither more nor less likely to have UTI antibiotic 
resistance in an ambulatory care setting when prescribed antibiotics initially for a UTI. 
Since the CI (confidence interval) was 0, the increased odds (.000) of UTI antibiotic 
resistance among nonpregnant females, ages 25-44, and on Medicaid, who were 
prescribed broad-spectrum antibiotics for UTIs at baseline, did not explain any statistical 
significance either way.  
Predictor characteristics and broad-spectrum antibiotics Predictor 
characteristics based on descriptive measures of incidence and prevalence were 
calculated for broad-spectrum antibiotics and UTI antibiotic resistance (see Table 18). 
The prevalence of UTI antibiotic resistance in the total number of sample cases with UTI 
antibiotic resistance (n=45) was 60% when prescribed broad-spectrum antibiotics. The 
incidence rate (new cases of antibiotic resistant UTIs) for those at risk in 12 months or 
less was 47%. 
 
Table 18 
 
Predictor Characteristics of Broad-Spectrum Antibiotics Prescribed  
 
 Prevalence Incidence  
Broad- 
Spectrum   
Antibiotics Prescribed   
 
60% 
 
47% 
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Narrow-spectrum antibiotics and binary logistic regression. The results of 
narrow-spectrum antibiotics as a predictor of UTI antibiotic resistance indicated that this 
was not a statistically significant predictor (R2.841(10), p= 44.837). AGES, REGION, 
INABXRX, and CONABXRX were controlled for. Thus, I failed to reject the null 
hypothesis (p>.05). The results of binary regression with narrow-spectrum antibiotics 
prescribed predicting UTI antibiotic resistance in 12 months or less can be reviewed in 
Table 19.  
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Table 19 
Summary of Binary Logistic Regression and Narrow-Spectrum Antibiotics  
 
Variables 
 
B Sig. β 
NS -19.73 
 
.998 .000 
AGES (1) -17.55 
 
.998 .000 
AGES (2) -15.93 
 
.998 .000 
AGES (3) 36.47 
 
.997 6.875E+15 
REGION (1) -.242 
 
.924 .785 
REGION (2) .382 
 
.845 1.47 
REGION (3) 18.06 
 
.998 69985861.09 
REGION (4) .574 
 
.805 1.78 
INABXRX 
 
-1.244 .537 .288 
CONABXRX 
 
-73.98 .996 .000 
Notes. R2 = .841 (p>.05) 
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To examine the fourth binary logistic regression model, the Hosmer and 
Lemeshow test was processed along with a classification table to check for the model fit. 
Hosmer and Lemeshow indicated that there was neither significant or insignificant 
improvement between the observed data in block 0 and the final regression model, 
therefore this model did not appear to be of a good fit (<.05) without an acceptable level 
(X2=.217(6), p=1.000). The results of the model summary concluded that between 63% 
(Cox & Snell R2)) and 84% (Nagelkerke R2) of the variation in UTI antibiotic resistance 
could be explained by the final model. The correct classification rate had increased by 
49% (51.1 to 91.1).  
A review of the variables in the equation were analyzed. The variable, narrow-
spectrum antibiotics prescribed (NS), did not appear to contribute to the model; narrow-
spectrum antibiotics prescribed was not statistically significant (p>.05, p= .998). The 
negative coefficient B (-19.726) indicated that the target group had less cases coded as 
“1” (narrow-spectrum antibiotics prescribed) than “0” (narrow-spectrum antibiotics not 
prescribed), and was not significant after controlling for the other variables. Age (AGES), 
Region (REGION), initial antibiotics prescribed (INABXRX), and continued antibiotics 
prescribed (CONABXRX) did not contribute to the model and were not significant 
(p>.05). The coefficient (B) revealed that the odds of UTI antibiotic resistance was .000 
more likely for those prescribed narrow-spectrum antibiotics. The Sig. (p>.05, .998) 
concluded that narrow-spectrum antibiotics prescribed were not statistically significant, 
therefore I failed to reject the null hypothesis; the data remains inconclusive because 
there is insufficient evidence at the alpha level of significance to reject the claim that   
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narrow-spectrum antibiotics prescribed are related to UTI antibiotic resistance. The odds 
for those patients who were prescribed narrow-spectrum antibiotics for symptomatic 
UTIs were .000 (95%CI .000 to .000) neither more nor less likely to have UTI antibiotic 
resistance in an ambulatory care setting when prescribed antibiotics initially for a UTI.  
Since the CI (confidence interval) was 0, the increased odds (.000) of UTI antibiotic 
resistance among nonpregnant females, ages 25-44, and on Medicaid, who were 
prescribed narrow-spectrum antibiotics for UTIs at baseline, did not explain any 
statistical significance either way.  
Predictor characteristics and narrow-spectrum antibiotics Predictor 
characteristics based on descriptive measures of incidence and prevalence were 
calculated for narrow-spectrum antibiotics and UTI antibiotic resistance (see Table 17). 
The prevalence of UTI antibiotic resistance in the total number of sample cases with UTI 
antibiotic resistance (n=45) was 49% when prescribed narrow-spectrum antibiotics. The 
incidence rate (new cases of antibiotic resistant UTIs) for those at risk in 12 months or 
less was 31%.  
 
Table 20 
 
Predictor Characteristics of Narrow-Spectrum Antibiotics Prescribed  
 
 Prevalence Incidence  
Narrow- 
Spectrum  
Antibiotics Prescribed   
 
49% 
 
31% 
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Combined broad- and narrow-spectrum antibiotics and binary logistic 
regression. Combined broad- and narrow-spectrum antibiotics were not statistically 
significant as a predictor of UTI antibiotic resistance within 12 months or less after the 
onset of UTI symptoms (R2.873(10), p= 47.818). Thus, I failed to reject the null 
hypothesis. The results of binary regression with combined broad- and narrow-spectrum 
antibiotics prescribed predicting UTI antibiotic resistance in 12 months or less (see Table 
21).  
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Table 21 
 
Summary of Binary Logistic Regression and Combined Broad- and Narrow-Spectrum 
Antibiotics  
 
Variables 
 
B Sig. β 
BSNS 51.61 
 
.995 2.592E+22 
AGES (1) -43.23 
 
1.00 .000 
AGES (2) -43.23 
 
1.00 .000 
AGES (3) 61.17 
 
.999 3.695E+26 
REGION (1) -18.57 
 
.996 .000 
REGION (2) 34.14 
 
.996 6.685E+26 
REGION (3) 37.71 
 
.999 2.392E+16 
REGION (4) -17.47 
 
.996 .000 
INABXRX 
 
-35.40 .995 .000 
CONABXRX 
 
-122.97 .994 .000 
Notes. R2 = .873 (p>.05) 
 
 
 
102 
 
To examine the fifth binary logistic regression model, the Hosmer and Lemeshow 
test was processed along with a classification table to check for the model fit. Hosmer 
and Lemeshow indicated that there was neither significant or insignificant improvement 
between the observed data in block 0 and the final regression model, therefore this model 
did not appear to be of a good fit (p<.05) without an acceptable level (X2=.000(6), 
p=1.000). The results of the model summary concluded that between 65%(Cox & Snell 
R2)) and 87% (Nagelkerke R2) of the variation in UTI antibiotic resistance could be 
explained by the final model. The correct classification rate had increased by 40% (51.1 
to 91.1.).  
A review of the variables in the equation were analyzed. The variable, combined 
broad and narrow antibiotics prescribed (BSNS), did not appear to contribute to the 
model; combined broad- and narrow-spectrum antibiotics prescribed was not statistically 
significant (p>.05, p= .995). The positive coefficient B (51.609) indicated that the target 
group had more cases coded as “1” (combined broad- and narrow-spectrum antibiotics 
prescribed) than “0” (combined broad- and narrow-spectrum antibiotics not prescribed), 
and was not significant after controlling for the other variables. Age (AGES), Region 
(REGION), initial antibiotics prescribed (INABXRX), and continued antibiotics 
prescribed (CONABXRX) did not contribute to the model and were not significant 
(p>.05). The coefficient (B) revealed that the odds of UTI antibiotic resistance was .000 
more likely for those prescribed combined broad- and narrow-spectrum antibiotics. The 
Sig. (p>.05, .995) concluded that combined broad- and narrow-spectrum antibiotics 
prescribed were not statistically significant, therefore I failed to reject the null hypothesis;   
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there was insufficient evidence at the alpha level to reject the claim that combined broad- 
and narrow-spectrum antibiotics prescribed is related to UTI antibiotic resistance. The 
odds for those patients who were prescribed combined broad- and narrow-spectrum 
antibiotics for symptomatic UTIs were 2.592E+22 (95%CI .000 to .000) more likely to 
have UTI antibiotic resistance in an ambulatory care setting when prescribed antibiotics 
for a UTI. Since the CI (confidence interval) was 0, the increased odds (2.592E+22) of 
UTI antibiotic resistance among nonpregnant females, ages 25-44, and on Medicaid, who 
were prescribed combined broad- and narrow-spectrum antibiotics for UTIs at baseline, 
were not statistically significant and therefore I failed to reject the null hypothesis.  
Predictor characteristics and combined broad- and narrow-spectrum 
antibiotics. Predictor characteristics based on descriptive measures of incidence and 
prevalence were calculated for combined broad- and narrow-spectrum antibiotics and 
UTI antibiotic resistance (see Table 22). The prevalence of UTI antibiotic resistance in 
the total number of sample cases with UTI antibiotic resistance (n=45) was 49% when 
prescribed combined broad- and narrow-spectrum antibiotics. The incidence rate (new 
cases of antibiotic resistant UTIs) for those at risk in 12 months or less was 31%.  
Table 22 
 
Predictor Characteristics of Combined Broad- and Narrow-Spectrum Antibiotics 
 Prescribed  
 
 Prevalence Incidence  
Combined  
Broad and Narrow- 
Spectrum  
Antibiotics Prescribed   
 
49% 
 
31% 
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Summary  
Three research questions, inclusive of five binary logistic regressions were 
conducted with the statistical program, SPSS, to examine possible relationships between 
the timing of antibiotic prescribing, either initial antibiotics prescribed within three 
months or less, or, antibiotics continued in 12 months or less, and, those classes of 
antibiotics prescribed for UTIs (broad-spectrum, narrow-spectrum, and combined broad 
& narrow-spectrum), and antibiotic resistance in urinary tract infections in nonpregnant 
females, ages 25-44, on Medicaid who sought care in an ambulatory setting. The first 
research question explored whether antibiotics prescribed at the onset of a UTI was 
associated with antibiotic resistance. The results of the first binary regression indicated 
that there was no impact on UTI antibiotics resistance within 3 months or less and initial 
antibiotics prescribed. Additionally, there was no impact with initial antibiotics 
prescribed and the age of the patient or the region where the visit took place. The second 
research question explored whether antibiotics that were continued for recurrent UTIs 
that had been initially treated previously in an ambulatory care setting, were associated 
with antibiotic resistance. Results of the second binary regression indicated that there was 
no impact on UTI antibiotics resistance within 12 months or less and continued 
antibiotics prescribed. Additionally, neither age or region was impacted by continued 
antibiotic prescribing. The third question explored whether the class of antibiotics 
prescribed for UTIs impacted antibiotic resistance. Results of the third binary regression 
indicated that there was no impact on UTI antibiotics resistance and broad-spectrum, 
narrow-spectrum, or combined broad- and narrow-spectrum antibiotics prescribed. 
105 
 
Additionally, there was no impact found with the age of the patient, or the region where 
the visit took place.  
The study findings will be investigated and explained further in Chapter 5. 
Chapter 5 will compare the findings with the literature review and background of the 
theoretical framework. Chapter 5 will additionally provide recommendations based on 
this study’s limitations, as well as examine the potential for social change while 
providing recommendations for future antibiotic prescribing practice in health care.  
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Chapter 5: Discussion, Conclusions, and Recommendations 
The purpose of this quantitative study was to examine nonpregnant U.S. female 
patients who were exposed to poverty, as evidenced by Medicaid, the reported payment 
type, and, at risk for antibiotic resistance when seeking care for UTIs in ambulatory care 
settings. The exploration of those relationship potentials with UTI antibiotic resistance 
and prescription timing laid the groundwork for larger cause-effect studies that should be 
conducted in the future. This study’s sample was small; however, findings indicate that 
the broad-spectrum class of antibiotics continue to be overutilized. Additionally, the 
prescribing of combined classes of antibiotics, broad- and narrow-spectrum, may be an 
increasing concern to consider and not simply an artifact results related to a small study.  
The significance of this research study is to distribute education associated with 
negative outcomes related to the inappropriate prescribing and utilization of antibiotics in 
the treatment of UTIs in an ambulatory clinic setting. Specific classes of antibiotics were 
selected to find out if these had an impact on UTI antibiotic resistance. Relationships that 
may occur between the timing of when antibiotics are prescribed and UTI antibiotic 
resistance were also examined. To my knowledge, this is the first study of its kind to 
utilize the NAMCS data to examine the relationships among antibiotic prescribing and 
UTI antibiotic resistance in low-income women in an ambulatory clinic setting.  
Five binary logistic regressions were executed with the three research questions 
posed utilizing a statistical program, SPSS 23. Binary logistic regression analyzed 
relationships between the timing of antibiotic prescribing and UTI antibiotic resistance.  
Before regression was carried out, descriptive statistics were executed; frequencies, cross  
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 tabs, and prevalence were calculated and reviewed. I found that 91% of nonpregnant 
women between the ages of 25-44 and on Medicaid and who followed up at an 
ambulatory care clinic were more likely to be prescribed broad-spectrum antibiotics 
initially and, also, when continued on antibiotics for a UTI. Women who required follow-
up for recurrent UTIs were continued on antibiotics 85% of the time; of those, 73% were 
antibiotic resistant to broad-spectrum antibiotics.  
Interpretation of the Findings 
The diagnosis and treatment of UTIs and their association with antibiotic 
resistance have significant implications for patient health and costs associated with health 
care (Magliano et al., 2012). According to Langdon, Crook, and Dantas (2016), research-
based studies in the United Sates are valuable for the identification of factors that may 
negatively alter resistance rates in underserved populations, such as nonpregnant women 
on Medicaid. However, pregnant female Medicaid populations have been the focus of 
UTI antibiotic research because of potential teratogenic effects on the fetus (Minardi et 
al., 2011). Efforts should be made to increase the prediction of antibiotic-related UTIs for 
the women on Medicaid and supported by financial, pharmaceutical, demographic data. 
Efforts should also be made to increase the research grants issued in this area.  
In the United States, the rate of UTIs are greater than 13,000 per 100,000 adult 
women per year (Kattan & Gordon, 2013). UTI prevalence studies appear to evidence 
wide fluctuations in reporting depending on the population being studied. Both pregnant 
and nonpregnant females have been reported to have the same prevalence rates with 
community-acquired UTIs, however, pregnant females have been the focus research   
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studies in the United States (Salem & El-Azab, 2011; Anozie, Lawani, Esike, Mamah, & 
Ajah, 2016).  
Literature reviewed for this study combined the most current study outcomes and 
research history related to community-acquired UTIs nonpregnant women in low-income 
populations in the United States. Females between the ages of 25-44 were found to be the 
most likely group to become resistant to antibiotics according to one of the earliest 
studies on UTIs and antibiotic resistance in an ambulatory setting (Butler, Hillier, 
Roberts, & Dunstan, 2006). In one large multi-year study between 2002-2008, over 35% 
of female patients on both Medicare and Medicaid were found to have uncomplicated 
UTIs, however, all study participants were over the age of 18, therefore age as a 
confounder was not controlled for and antibiotic utilization and resistance were not 
discussed.                                                                                                                                         
The mean age for nonpregnant women in my study population who developed 
antibiotic resistance in uncomplicated UTIs was 33 years of age (age range 25-44). This 
was consistent with the uncomplicated study element and findings by Kobayashi et al 
(2016) indicating that women in the age range of 30-49 had a higher percentage of 
uncomplicated UTI occurrences in ambulatory care settings (35%). Kobayashi et al, 
however, did not incorporate antibiotic utilization and resistance factors into their study. 
Geographically, my study evidenced a higher occurrence with uncomplicated UTIs in 
low-income women in the Southern region of the United States than other states. The 
Southern U.S. regional data reported by Kobayashi et al. was consistent with my study 
finding that the Southern United States had the highest rates of occurrence (27%) in   
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uncomplicated UTIs. My study however, produced a small reduction in occurrence 
outcomes with uncomplicated UTIs in low income females from the South (44%) 
compared to the Western United States (24%). However, both the South and the Western 
regions of the United States had a higher percentage of UTI occurrences than the 
Northeastern (22%) or Midwestern (16%) United States. As I could not find similar 
studies conducted to date in the Unites States related to uncomplicated UTIs in low-
income female populations, I used references of results identified in global studies.  
Broad-spectrum antibiotics are the most appropriate class of antibiotics in the 
empiric treatment of UTIs (Merli et al., 2016). They are normally prescribed for just a 
few days of treatment after the initial diagnosis, however it is becoming more common to 
find UTIs that need prolonged treatment (Mazzulli, 2012; Lamb, 2016). Antibiotic 
resistance may occur when a provider fails to order a timely urine culture, or, the 
laboratory does not reflex a urine test when the urinalysis meets a specific threshold 
(Eliopoulis, Cosgrove, & Carmeli, 2003; Wolf, 2016); as a result, inappropriate 
antibiotics are prescribed (Humphries & Dien Bard, 2016). This type of care can increase 
resistance patterns either already present, or provides an environment for resistance to 
occur (Lee, Cho, Jeong, & Lee, 2013).                                                                                                                                                                               
 This study indicated that 91% of nonpregnant females on Medicaid were 
prescribed antibiotics initially for symptomatic UTIs. Of these patients, 84% were 
continued on antibiotics in 12 months or less. This means that only 7.2% of the Medicaid 
nonpregnant female population who were initially prescribed antibiotics may not have 
been treated adequately or appropriately and had to return for further UTI antibiotic   
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treatment. Of those patients (initial and continued combined) who were prescribed 
antibiotics and became resistant, 79% were prescribed broad-spectrum antibiotics, 31% 
were prescribed narrow-spectrum antibiotics, and 57% were prescribed a combination of 
broad- and narrow-spectrum antibiotics. This study’s sample outcomes appeared to be 
consistent with current treatment guidelines indicating that the administration of broad-
spectrum antibiotics should be reduced for suspected UTIs (Goodman et al, 2016); 
providers appear to be overprescribing broad-spectrum antibiotics. Although not included 
in the analysis, this study’s initial case review anecdotally noted that fluoroquinolones 
were the primary broad-spectrum category of antibiotics prescribed initially for UTIs.  
Most of the nonpregnant female Medicaid cases in the sample population (n=45) 
had evidence of UTI signs and symptoms per the NAMCS codebook; 89% of the sample 
was recorded as having a UTI signs and symptom. Those patient cases that did not have 
signs and symptoms evident, had a UTI diagnosis code present per ICD-9 coding (5990). 
Access to a complete medical chart was not available to review the rationale for those 
sample cases that did not meet UTI signs and symptoms study criteria (11%, or, 5 cases) 
but were coded as a UTI (5990). Several cases in the sample additionally did not meet for 
UTI resistance criteria, but were noted to have been prescribed initial or continued 
antibiotics. The initial or continued antibiotics coded in relation to UTI resistance was 
documented with an ICD-9 diagnosis code for a medical condition other than UTI, even 
in the presence of an ICD-9-documented UTI code, therefore these cases did not meet 
criteria for UTI antibiotic resistance. Since each of the patients in the sample had 
laboratory evidence of a urinalysis and had an ICD-9 code of “5990” documented, initial   
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or continued antibiotics should have been prescribed according to practice 
recommendations (IDSA, 2011).   
Ecosocial Theory and Interpretation of Findings 
In Chapter 2, I described an ecosocial interactive method of analysis framework 
for disease inequalities, distribution, and a population’s health (Krieger, 2008). As a 
result, the study increased the understanding for one social determinant, poverty, as 
evidenced by Medicaid, and the roles/influential characteristics that prescribing any class 
of antibiotic at any stage of a UTI, has on the nonpregnant female population. Population 
health distribution (health outcomes) includes antibiotic susceptibility (Penders, 
Stobberingh, Savelkoul, & Wolffs, 2013) as well as other tangible and psychological care 
for a UTI, all of which are at the heart of population distribution. Pathways from health 
distribution leads to the process of UTI treatment. Inequalities of class, race, ethnicity, 
and gender surround population health distribution as these pathways are traveled. 
Healthcare-provider competency weighs heavily on antibiotic exposure outcomes, and 
these prescribing decisions are often not based on hard evidence (lab test results, for 
example), but based on the interactions between the patient and provider (Meropol, 
Mercalio, & Metlay, 2013).   
Studying a social determinant was pertinent in the analysis of poverty and 
antibiotic resistance. The ecosocial theory approach anticipates large and small scale-
level effects on a social determinant such as poverty and health outcomes (Krieger, 
2005). Additionally, individual beliefs are determinants on a patient’s health outcome 
which can affect every aspect of a patient visit (Krieger, 1994; Krieger, 2001; Krieger,   
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2008). Every woman that experiences poverty in this study must be able to reference how 
their care should be when they go to an ambulatory care setting with symptoms of a UTI. 
They should be able to intrinsically evaluate how decisions for their care are made so that 
they can deter future risks of occurrence or recurrence. Group-level knowledge is also 
important, especially today with social media (Krieger, 2008; Krieger, 2012). An 
individual can connect with others on the internet and find out about experiences, or, 
access how providers are “graded” (Woods et al., 2013). Each patient, no matter what 
language they speak or what social class they are from should be able to understand what 
constitutes treatment with dignity by the provider and other health care staff (Dickert & 
Kass, 2009); those with disabilities will have to rely on their caregiver for this, which 
may or may not be a bias (Seibert, Stridh-Igo, & Zimmerman, 2002) on the pathway to 
care.  
Disadvantaged groups have been known to have barriers with access to care, and, 
those processes that affect appropriate management (Artiga, 2016). A Harvard staff 
writer stated, “You don’t have to travel all the way to Malawi, you can go to any rural 
house in America” (Powell, 2016, p.1) (regarding where to find overlooked health 
inequalities). Inequalities are representative of the structural inequalities found in society 
that include economic, political, and social (Krieger, 2012). Determinants can influence 
UTI antibiotic management and access to the right provider, laboratory, diagnostic, or 
pharmacy services. The distribution of nonpregnant females on Medicaid that encounter 
symptoms of a UTI may will go one of two ways: the UTI goes away after initial   
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antibiotics are prescribed, or, the UTI is recurrent and antibiotics must be continued. 
Either way the Medicaid patient must be treated the same as any other patient.  
The complexity with both initial antibiotic prescribing and continued antibiotic 
prescribing for UTIs can further influence the ecosocial diagram. These aspects of care 
by medical providers will significantly impact a patient’s health outcome and future 
outcomes. Unfortunately, when a symptomatic patient presented for care in my study, 
due to not having access to a complete medical chart that could have documented other 
signs and symptoms of UTI, the review of the provider’s choice of antibiotics, and 
objective, and subjective content, could not be ascertained. Several cases clearly did not 
have antibiotics issued, although they had positive signs and symptoms of a UTI and had 
a urinalysis performed. Many Medicaid patients who were prescribed antibiotics at their 
initial appointment also came back to be re-treated for their UTIs. There was additionally 
evidence of no treatment, yet Medicaid patients returned to their provider for treatment, 
therefore, treatment occurred after the initial appointment somewhere. It is unknown 
without a complete medical record, whether there was a reason noted by the provider 
about why antibiotics were not prescribed for a positive urinalysis and signs and 
symptoms of UTI criteria were met and if the patient was referred to an ED for treatment.  
My study supported findings that a urinalysis should be conducted and antibiotics 
prescribed for complaints if UTI symptoms were also present (Bates, 2013). A urinalysis 
is not recommended for asymptomatic bacteriuria (Abbo & Hooton, 2014). There were 
no patients in my study with asymptomatic bacteriuria who underwent a urinalysis, and 
coded with a UTI. Studies in the literature have concluded that in the presence of positive   
114 
 
nitrites and leukocytes found on a urinalysis (Simon, 2012), however, a UTI should 
always be included in the differential as it is usually indicative of a bacterial UTI; a 
bacterial UTI in the presence of positive symptoms and patient history should always be 
treated with an appropriate antibiotic (Mody & Juthani-Mehta, 2014).   
An initial review of the data collected for my study before analysis was conducted 
indicated that 3 out of 45 (7%) patients returned to their primary care provider for a 
recurrent UTI and was prescribed initial antibiotics elsewhere. Therefore, these Medicaid 
patients saw their provider, were not treated, went elsewhere for care for their UTIs, were 
prescribed antibiotics, then returned to the original healthcare-provider that they saw 
initially because they were still having UTI symptoms. A diagnosis code was created to 
represent a UTI when the Medicaid patients were initially seen, however, they were not 
prescribed initial antibiotics. This information is consistent with one study that reported 
that after an initial diagnosis in primary care was made, an emergency department (ED) 
visit will occur 68% of the time, or, 180 days from the original diagnosed medical 
condition (Lash et al., 2017). Without the full medical chart, I was unable to deduce 
where the initial antibiotics prescribed had come from. It was already known that their 
primary providers that they saw initially when their UTI symptoms first occurred, were 
present, as indicated by the data, however they were not prescribed initial antibiotics. I 
could have hypothesized that these patients consulted with an ED after they did not 
receive initial UTI treatment from a primary provider. However, again, without the full 
medical chart, I was unable to confirm this for this study.   
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Evidence that patients on Medicaid are seeking care for simple medical problems 
in an ED or urgent care clinic is much costlier for treatment than by a primary provider 
and not appropriate (Kellermann & Weinick, 2012). Patients on Medicaid should not 
have to resort to an ED or urgent care clinic for the care of an acute, uncomplicated UTI. 
According to Kellermann & Weinick (2012), in a study that spanned two decades, 
involved anonymous callers who phoned primary care clinics posing as Medicaid patients 
and asked if they accepted Medicaid for minor treatment. When the answer was “no” 
they did not accept Medicaid, there was a 26% response-rate of being referred to an “ED” 
for treatment. My study supported findings by Kobayashi et al that initial treatment with 
antibiotics by a primary care provider for UTIs (2016) should be recommended for those 
patients on Medicaid and not an ED (2012; Trinh & Klinker, 2015). This was evidenced 
in my study with 26 out of 45 Medicaid patients (58%) that had to undergo continued 
treatment (recurrence) of the initial UTI; Medicaid patients should be afforded the same 
continuity of care as anyone else. Therefore, were those 3 patients possibly told upon 
discharge from their own primary care provider to follow up at an ED if they had any 
further problems versus coming back for care again? Siek, Hefner, Wexler, Taylor, & 
McAlearney (2016) found that cultural and other educational issues may be a barrier to a 
patient’s perception of their need for an emergency department.  
Patient’s truly may not understand why they would be referred for further 
problems to an ED, if it also was not explained that care for the same problem, that was 
not an emergency, should bring them back to their primary care provider. Education with 
the medical staff about how to communicate with patients should always be reviewed by   
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another competent medical staff supervisor (Gesme, Towel, & Wiseman, 2017). A 
Medicaid patient who is seen in an ED for an uncomplicated UTI after being diagnosed 
in a clinic, then re-treated in the ED, is disadvantaged because the provider that they 
return to after an ED appointment, may not have laboratory results or other diagnostic 
information to enable them to continue these patients on antibiotics appropriately, 
whereby, creating an environment for UTI antibiotic resistance.   
Interpretation of Statistical Findings 
The sample of 45 nonpregnant female patients, ages 25-44, and on Medicaid were 
all positive for UTI diagnosis, yet 41 (91%) of these patients received initial antibiotics in 
3 months or less. Of the 41 patients who were prescribed antibiotics in 3 months or less, 
21 (51%) became UTI antibiotic resistant. Of the 41 patients who received initial 
antibiotics and became UTI antibiotic resistant, 11 (27%) received a broad-spectrum 
antibiotic, 4 (10%) received a narrow-spectrum antibiotic, and 4 (10%) received a 
combined broad- and narrow-spectrum antibiotic. Of the sample (n=45), 26 patients 
(58%) were continued on antibiotics within 12 months or less from their initial UTI 
diagnosis. Of the 26 patients who were continued on antibiotics, 22 (85%) became UTI 
antibiotic resistant. Of the 22 patients who received continued antibiotics in 12 months or 
less and became UTI antibiotic resistant, 16 (73%) were prescribed broad-spectrum 
antibiotics, no patients were prescribed narrow-spectrum antibiotics, and 3 (14%) were 
prescribed combined broad- and narrow-spectrum antibiotics. Of the sample (n=45) who 
became UTI antibiotic resistant, 3 (7%) were prescribed both broad-spectrum and a 
combined broad- and narrow-spectrum antibiotic on the initial appointment; patients were   
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never prescribed combinations of narrow-spectrum or combined broad- and narrow-
spectrum at their initial appointment. Therefore, my study findings indicated that over 
half (51%) of those non-pregnant females, ages 25-44 and on Medicaid, who were 
prescribed antibiotics during their initial appointment in ambulatory care for UTI 
symptoms, became UTI antibiotic resistant. The predominant antibiotic prescribed that 
was associated with UTI antibiotic resistance was broad-spectrum antibiotics. 
Additionally, this study indicated that 84% of those nonpregnant females between 25-44 
years of age and on Medicaid who followed-up with recurrent UTI symptoms, and were 
prescribed antibiotics, and had a positive outcome of UTI antibiotic resistance, were 
predominantly prescribed broad-spectrum antibiotics. These findings concur with Shapiro 
et al (2013) who conducted the only adult study published in the United States at th333is 
time on antibiotic utilization in an ambulatory care setting, that concluded that broad-
spectrum antibiotics were prescribed more than any other antibiotic.    
Limitations of the Study 
There are multiple study limitations that need to be acknowledged.  First, this 
study was limited using secondary data; I neither directed nor supervised the collection of 
the survey data. The second limitation was the relatively small sample size. Data was 
assumed to be accurately collected, however, prior to the year 2012 the category code 
describing gestational status identified as “Pregnant” (NAMCS, 2012) was not available 
as a variable for analysis. To compensate for the absence of an all-inclusive variable and 
ensure internal validity of this status prior to 2012, NAMCS code books were used to 
identify codes related to pregnancy. Possible underreporting of UTI   
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diagnoses may have been related to erroneous sampling and coding errors in the sample 
frame as evidenced by the limited number of UTI cases identified for this study. Other 
research studies that have utilized NAMCS data have also expressed the possibility with 
potential coding issues (May, Mullins, & Pines, 2014). During data validation of the 
secondary data source codes for my study, NAMCS secondary codebook codes were 
substituted for ICD-9 codes at times resulting in errors in the interpretation of a 
diagnosis, therefore those cases were not included. All codes were reviewed for accuracy 
during my study’s internal validation process. 
The final case count after all related codes were abstracted indicating that only 51 
cases of UTIs were recorded. I questioned this and made an inquiry to NAMCS. NAMCS 
responded with a concurrence to my findings, except that they found even less than I had 
because they did not include both upper and lower UTI codes, only those that were coded 
specifically as “UTI” (ICD-9 code 5990). A closer review may indicate that there is 
substantial underreporting with UTIs, or, coding errors are an issue in ambulatory care 
settings. Global research studies provide data that strongly support the notion that low-
income nonpregnant women between the ages of 25-44 who have been treated in 
ambulatory care clinics for uncomplicated UTIs are a high-risk population that deserves 
to be further studied.  
The sample frame represented all 4 census regions of the United States. Each 
population variable (nonpregnant, female, and Medicaid) was represented in this national 
survey. My choice of conducting a retrospective cohort study narrowed the availability of 
potential confounding factors resulting in selection bias (Euser, Zoccali, Jager, & Dekker,   
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2009; LaMorte, 2016) however, a prospective study would have been hindered by time 
and expense (Song & Chung, 2010). Song and Chung (2010) stated that a retrospective 
study is a refined and efficient way to conduct research studies because of the ability to 
use historical data. Fisher’s exact test was the obvious choice for analysis due to the small 
number of cases. The smaller sample produced an overestimation in the odds ratios which 
was due to the use of logistic regression (Nemes, Jonasson, Genell, Steineck, 2009). A 
larger study sample may have produced more robust results by providing an adjustment 
with additional confounders, and decreased the potential for a biased odds ratio that may 
have led to an overestimation of the effect measure.  
At this time, there is no gold standard available to measure how to prevent 
uncomplicated UTI antibiotic resistance in nonpregnant women. There is no way to know 
the sensitivity and specificity of implied analysis. Confounders such as geographical 
regions were used because according to the literature search antibiotic susceptibility, 
because of inappropriate utilization patterns, regional politics, or regional patient 
behaviors and access to care, are related to antibiotic resistance. A larger study to assess 
the causal effects of geographical region on antibiotic resistance would be recommended 
and this study was limited by the choice of study design. 
Generalizability was lacking in my study due to the unexpected small sample size. 
A more detailed sample frame of data related to regions, age ranges, and specific 
antibiotics that were prescribed for uncomplicated UTI cases could have been used to 
substantiate generalizability. Random sampling was conducted because it is not rational 
to study an entire population (Kukull & Ganguli, 2012), however this did not improve   
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external validation. Kukull & Ganguli (2012) posit that when a study is comprised of 
clinic visits, it is less important to focus on generalizability and more important to capture 
the accuracy in diagnostics. The authors explain that any study’s results that are clinic-
based can become negatively skewed if the disease in question is not identified properly, 
and, any misclassification of disease (those that are positively versus negatively 
diagnosed) may diminish and misconstrue results of a study (Kukull & Ganguli, 2012).  
Internal validation for my study clearly confirms that the disease was classified properly. 
The extent to which my study results could be generalized may be a consequence in 
choice of confounders controlled for. This study explored age and region as confounders 
because of the associations with antibiotic resistance exposures already documented in 
UTIs. This introduction was used to attract other researchers and motivate towards the 
engagement of future research in this area.  
The third limitation was that this study did not allow inference for causes and 
effects, therefore data associations were limited. Underlying medical conditions and 
detailed antibiotic dosing that could have been associated with UTI symptom 
management and antibiotic resistance were found to be unreliable for analysis. For 
example, indicators often used to “define daily dose (DDD)” (p. 5) according to 
Schechner, Temkin, Harbarth, Carmeli, & Schwaber (2013) in cohort studies were not 
available. DDD may over-, or, under- generalize results (Schechner et al., 2013). Further 
analysis of appropriate variables that are time-dependent may be one key to inappropriate 
antibiotic prescribing for UTIs. This may be accomplished by the interpretations of the 
relationships between the initial provider appointment activities and future appointments   
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linking the same patient with continued UTI symptoms. The final limitation was 
evidenced by the analysis outcomes for initial and continued prescribing of antibiotics 
and antibiotic resistance. Initial and continued prescribing of antibiotics hypothesized as 
factors contributing to antibiotic resistance was not found to be statistically significant. 
The allocation and timing of antibiotics once a patient was discharged could not be 
determined.  
Recommendations 
Future research to overcome the limitations found in this study is crucial. Data 
must be thoughtfully collected and interpreted so that the results can be applied to actual 
ambulatory care settings. Although the sample size was small and generalizability was 
difficult to produce, the obvious overutilization of the broad-spectrum class of antibiotics 
evidenced by this study’s outcomes substantiates the notion that these antibiotics are the 
main cause for antibiotic resistance (CDC, 2013). It is recommended that subsequent 
studies should attempt to include medical record details from a broad, general, 
nonpregnant female Medicaid ambulatory care population, between the ages of 25-44, 
that is a nationally representative sample, and anticipate if antibiotics are clinically 
indicated for UTIs. This information should be utilized for a cause and effects study that 
can interpret those barriers with antibiotic prescribing and resistance in this population. 
This data may then potentially be utilized by a team of companies, private and public, 
such as pharmacies, laboratories, emergency departments, and ambulatory health clinics, 
to put their resources together and propose a plan for antibiotic prescribing. Conditions 
that lead to hospitalizations, known as ambulatory care-sensitive conditions (ACSC)   
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appear to also be prevalent (Mkanta, Chumbler, Yang, Saigal, & Abdollahi, 2016) with 
UTIs. Many studies have already shown that there are multiple disconnects and barriers 
to appropriate prescribing that are dependent on the many levels related to type of care 
that a patient must receive once they are symptomatic with a UTI (Hossain & Laditka, 
2009; Kellermann & Weinick, 2012). 
The need to include a larger sample is highly recommended due to the altered 
relationships that were seen with the distribution and odds ratios with binary logistic 
regression; the power needs to be increased. Variables that are more robust would serve 
this study well. The variables of age and region in this study, although categorized 
appropriately, did not provide enough of a relationship and the outcome was a poor 
model fit. Statistical significance may have improved, however, possibly age and region 
may have seen a more generous relationship had the sample size been larger.  
Antibiotic class-induced antibiotic resistance has been well documented (Harbarth 
et al., 2015; Ventola, 2015) while the discrete prescribing of nonpregnant Medicaid 
females in the development of UTI antibiotic resistance has not (Minardi et al., 2011; 
Eells, Bharadwa, McKinnell, & Miller, 2014). Studies that could utilize U.S. licensed 
antibiotic agents of all classes to treat UTIs with nonpregnant female Medicaid 
populations would augment the knowledge currently published and identified by this 
literature gap.   
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Implications 
 
 This study’s’ conclusions afforded an improved understanding of UTI antibiotic 
resistance epidemiology in this distinct, and impoverished UTI-positive population. This 
study additionally provided significant implications for social change. An improved 
understanding can be groundbreaking for new areas of inquiry, and lead to necessary 
future studies. The main goal of antibiotic stewardship in the United States and globally, 
is to minimize potential harm that may come to patient’s due to the inappropriate 
treatment of antibiotics. UTI incidence of antibiotic resistance before and after 
implementing antibiotic stewardship programs has been described across the United 
States, however, this has only been studied in hospitalized patients, pregnant women, or 
long-term care patients with urinary catheters (May, Mullins, & Pines, 2014; Shapiro et 
al., 2013; Mkanta et al., 2016).  
Antibiotic stewardship is new to ambulatory care clinics; infection control 
surveillance, other than outpatient surgery, and more recently, outpatient dialysis (CDC, 
2011c, p. 1), currently does not have a way to appropriately collect denominator data.  
Recent government attention though has created grants and other opportunities for study 
in order to create appropriate surveillance programs for ambulatory care (Magill, 
Dumyati, Ray, & Fridkin, 2015). This research study revealed that there continues to be 
inappropriate prescribing with broad-spectrum antibiotics in particular, but additionally, 
narrow-spectrum and combined broad- and narrow-spectrum. Additionally, follow-up 
visit communication after the initial antibiotic have been prescribed to nonpregnant 
females on Medicaid appears to be an issue. Therefore, the need to further study   
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communication activities upon discharge in outpatient settings with nonpregnant 
Medicaid when they are prescribed antibiotics could be a crucial step in antibiotic 
stewardship endeavors. Organizational and local levels in outpatient medicine could be 
influenced from epidemiology studies produced about nonpregnant female Medicaid 
patients’ timing of antibiotics and discharge communication.  
The relationship between antibiotic delivery in ambulatory care settings and the 
epidemic crisis of antibiotic resistance may benefit health-care providers. This may be 
related to communication education that has been in the spotlight for informing 
prescribing decisions that they will have to make. To implement comprehensive 
evidence-based measures with communication education for health-care providers about 
impoverished nonpregnant women and UTI antibiotic stewardship, more research studies 
are greatly needed, however individual state legislation and Medicaid also should be a 
priority for legislation. Antibiotic stewardship that leads to resistance with UTIs in the 
population are current health care issues affecting ambulatory care settings where 
Medicaid patients are often seen for care. Disparities in health care and poverty have 
been persistent and long-standing because Medicaid has not been expanded in 19 states in 
the United States; as of 2017, the coverage gap under the Affordable Care Act (ACA) 
remains uncertain because of the ability for states to opt out (CNBC, 2016; KFF, 2016; 
Johnson, 2016; Advisory Board, 2017).  
Ambulatory care patients on Medicaid need to increase their understanding of 
how UTIs are contracted to prevent or decrease antibiotic resistance and further 
complications that could result because of inappropriate treatment that includes antibiotic   
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prescribing. The key to prevention is active participation regardless of social economic 
status (Vahadat, Hamzehgardeshi, Hessam, & Hamzehgardeshi, 2014). The internet is 
free and available to anyone, in locations such as the library, schools, or even public 
health clinics. Also, in today’s modern world, even those on Medicaid may be eligible to 
have a free cellular telephone, which may come with internet access (Federal 
Communications Commission, 2017). Individuals who arm themselves with antibiotic 
knowledge are be more likely to take their medications as prescribed, or, discuss the 
rationale for an antibiotic prescribed before even taking it (Awad & Aboud, 2015).   
These proactive interventions are likely to reduce health care visits to ambulatory 
settings as well as hospitalizations for complications of UTIs. This would unfortunately 
need to be under tight surveillance; a resource not a priority in the ambulatory care 
setting. The person(s) providing the surveillance would need to be able to promptly report 
data to the providers onsite as well as educate them in the moment. Awareness at the time 
that a decision is made that could have a negative impact (active surveillance required), 
rather than passive, or, retrospective surveillance, and, education that may be lost to 
meaning as time moves beyond the problem, is needed. Real-time data that shows a 
healthcare-provider what their decisions are doing, will impact the patients’ future care. 
Health-care providers usually want to do what is right for any patient. There are 
providers, however, who have practiced medicine a certain way for such a long time, and 
may severely resist change, no matter how much data they are shown. These providers 
may also be reluctant to engage in any educational confrontations and may take offense 
to someone proposing to do this, even to help them and improve their patients’ care   
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outcomes (Sillito, 2016). Although for our canine brethren, an old dog may learn slower, 
but they will be able to learn a new trick (Coren, 2016), this does not decrease the 
necessity for provider responsiveness to antibiotic resistance education. Cross-cultural 
education may be stated as a “soft science” (Kripalani, Bussey-Jones, Katz, & Genao, 
2006, p. 1118), however, a reduction in morbidity and mortality that can be clearly 
viewed, may be the positive after-effect when communication education is provided to 
those that prescribe to the underserved population.  
Conclusions 
The purpose of this retrospective observational cohort study was to investigate 
nonpregnant American female patients on Medicaid who were at risk for UTI antibiotic 
resistance. The aim of this study was to understand the relationships between prescription 
timing and classes of antibiotics that were prescribed for uncomplicated UTIs treated in 
an ambulatory care setting. The regression analysis for the three research questions did 
not prove to be significant. However, this small study pointed at the same indications 
about antibiotic resistance that is currently found in the literature; broad-spectrum 
antibiotics are overutilized no matter when they are prescribed and are likely the 
offenders of antibiotic resistance in UTIs.  
The descriptive statistics results, proved to be worthy of analysis. This activity 
provided evidence in support of continued antibiotic research. Rearranging the class of 
antibiotic accordingly may decrease the number of those returning with recurrent UTIs. 
Specific antibiotics within the classes was not analyzed in this study. Furthermore, this 
study had indicated that there was a minuscule trend that may be indicative of poor   
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discharge communication. This was evidenced by a lack of antibiotic prescribed at the 
initial appointment, however, the recurrence of UTI symptoms and a return appointment 
indicated that antibiotics were continued. This was worrisome for both the patient and the 
provider. The patient, without clear discharge instructions may have misinterpreted being 
told to go to an emergency room if the problem continued. This could have been 
remedied by simply saying to return to the provider office if the problem continued, or, 
state that only in the case of an emergency (and provide parameters that the patient can 
understand, such as a fever of 104 or greater) they may need to go to an emergency room 
for care. Consistent messaging is an important piece of a patient care visit no matter what 
type of patient the care is for, or where they decide to go for care. It is important to 
remember that the patient has choices and will go where they feel comfortable and cared 
for.  
Future research with antibiotic stewardship should target UTI antibiotic resistance 
reduction endeavors to decrease UTI resistance frequency by addressing inappropriate 
prescribing and utilization in the nonpregnant female Medicaid population. This study 
portrayed the need to focus future research on appropriate antibiotic prescribing and 
make it a primary goal to include disparate populations, such as those on Medicaid. The 
ultimate focus, however, should be on decreasing unintentional negative outcomes of 
antibiotic prescribing practices.   
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